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A series of pentapeptide derivatives containing α,α-disubstituted α-amino acids have 
been prepared by a combination of the ‘azirine/oxazolone method’ and segment 
condensations. X-ray crystal-structure determinations of the molecular structures confirmed 
the presence of helical conformations stabilized by β-turns of type III or III’. Pentapeptides 
containing (R)-Phe(2Me) form a right-handed helix, whereas those containing (S)-Phe(2Me) 
adopt a left-handed helical structure. 
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1. Introduction. – Since the elaboration of the ‘azirine/oxazolone method’ as a 
convenient protocol for the synthesis of Aib-containing peptides [1–3], this procedure has 
been used successfully for the preparation of model peptides [2c][3–6], sterically congested 
oligopeptides [7][8], and peptaibols [2d][9–11]. It has also been shown that the method can be 
adopted to solid-phase methodology [12]. Another modification allowed the synthesis of 
endothiopeptides containing Aib units [13–16]. 
In the present study, a series of Z-protected pentapeptides containing α,α-disubstituted 
α-amino acids were prepared according to this method. All α,α-disubstituted α-amino acids 
were introduced via coupling of amino or peptide acids with 2,2-disubstituted 2H-azirin-3-
amines. The synthon for Phe(2Me) was the racemic 2-benzyl-2,N-dimethyl-N-phenyl-2H-
azirin-3-amine leading to mixtures of (R)- and (S)-Phe(2Me)-peptides2). In the case of 
diastereoisomers, they were separated chromatographically. 
Based on the studies of Ramachandran et al. [18] it is well-known that the 
introduction of α,α-disubstituted α-amino acids3) into peptides stabilizes β-turn and 310-
helical conformations [19][20]. For the crystalline state, this has been proven by X-ray 
crystallography (e.g., [21][22]). In spite of this knowledge, current interest in conformations 
of small peptides is documented by several recent reports (e.g., for pentapeptides [23][24]). 
For this reason, we determined the crystal structures of some of the prepared pentapeptides. 
 
2. Results and Discussion. – 2.1. Synthesis of Pentapeptides. The syntheses of the Z-
protected pentapeptides were carried out via combinations of the coupling of amino or peptide 
acids with 2H-azirin-3-amines and standard coupling with amino acid esters or peptide 
2)  Synthons for enantiomerically pure (R)- and (S)-Phe(2Me) are now also available 
[4a][17]. 
3)  The prototype is α-aminoisobutyric acid (Aib). 
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segments. Two examples are shown in Scheme 1: Following the procedure described in 
[11][25], Z-Gly-OH in THF was reacted with 2,2,N-trimethyl-N-phenyl-2H-azirin-3-amine 
(1a, Aib synthon [26]) leading to dipeptide amide 2, followed by selective hydrolysis to give 
Z-Gly-Aib-OH (3). Reaction of the latter with 2-benzyl-2,N-dimethyl-N-phenyl-2H-azirin-3-
amine (1b) [26b] yielded the tripeptide amide 4a [25a], which was hydrolyzed (→ 5a), 
coupled with 1a (→ 6a) and again hydrolyzed (→ 7a). The coupling of 7a with H-Gly-OMe 
and H-Phe-OBn, respectively, was carried out in CH2Cl2 using PyBOP/DIEA4) as the 
coupling reagent, leading to pentapeptide 8a5) and 8b, respectively. The latter was obtained as 
a 1:1 mixture of diastereoisomers. 
 
Scheme 1 
 
Similar to the preparation of 8a and 8b, pentapeptide 8c containing 1-
aminocyclobutane carboxylic acid (Acb) was synthesized (Scheme 2). Coupling of 3 with 2-
(N,N-dimethylamino)-1-azaspiro[2.3]hex-1-ene (1c) [2b] gave the tripeptide amide 4b in 87% 
yield. The hydrolysis of the terminal amide group was achieved in 3N HCl (THF/H2O) at 40° 
leading to 5b (96%). Subsequent azirine coupling with 1a (→ 6b), selective hydrolysis at 
room temperature (→ 7b), and coupling with H-Gly-OMe by treatment with PyBOP/DIEA 
gave 8c. 
 
Scheme 2 
4)  PyBOP = [(Benzotriazol-1-yl)oxy]tripyrrolidinophosphonium hexafluorophosphate; 
DIEA = ethyl(diisopropyl)amine (Hünig base). 
5)  The coupling of 7 with H-Gly-OMe was also achieved by treatment with DCC, ZnCl2, 
and Et3N in DMF [27][28] leading to 8a in 70% yield. 
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The Pro-containing pentapeptide 8d was obtained by segment coupling of 3 and H-
Pro-Aib-Aib-N(Me)Ph (9) in CH2Cl2 with HBPyU/DIEA6) as the coupling reagent [29] 
(Scheme 3). The tripeptide 9 [25b] was prepared by subsequent coupling of Z-Pro-OH with 
azirine 1a, selective hydrolysis, again coupling with 1a, and deprotection of the N-terminus 
by hydrogenolysis. Selective hydrolysis of 8d under the usual conditions gave the 
pentapeptide acid 10 in 70% yield. 
 
Scheme 3 
 
The pentapeptides 8e and 8f were prepared via coupling of the dipeptide segment 11 
[25a] with the tripeptide segment 12 and the corresponding H-Gly-Aib-Aib-N(Me)Ph [25a], 
respectively (Scheme 4). The coupling was performed by treatment with PyBOP/DIEA in 
CH2Cl2 at room temperature and led to 8e as a 1:1 mixture of diastereoisomers in almost 
quantitative yield. The corresponding 8f was isolated in 82% yield as a racemate. The 
segment 12 was obtained by coupling of 3 with H-Phe-OMe (PyBOP/DIEA; 85%), followed 
by hydrogenolytic deprotection of the NH2 group (98%). The diastereoisomers of 8e were 
separated chromatographically (SiO2, AcOEt/MeOH), and the pure isomers were isolated in 
47% ((S,S)-8e) and 44% ((R,S)-8e) yield. The configuration of (S,S)-8e was determined by X-
ray crystallography (see chapter 2.3). 
 
Scheme 4 
 
6)  HBPyU = O-[(Benzotriazol-1-yl)oxy]dipyrrolidinocarbenium hexafluorophosphate. 
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Finally, the dipeptide segment 11 was coupled with the tripeptides H-Pro-Aib-Phe-
OMe (13) and the corresponding H-Pro-Aib-Aib-N(Me)Ph [25b], respectively, leading to 
pentapeptides 8g and 8h (Scheme 5). These couplings proved to be rather difficult. In the case 
of 8g, the reaction with PyBOP/DIEA in CH2Cl2 for 19.5 h gave the product in only 39% 
yield, whereas with TBTU/HOBt/DIEA7), after 19.5 h, 8g was isolated in 74% yield. Also in 
the case of 8h, TBTU/HOBt gave slightly better results than PyBOP/DIEA. The tripeptide 13 
was prepared by coupling of Z-Pro-Aib-OH [25b] with H-Phe-OMe by treatment with 
PyBOP/DIEA. 
 
Scheme 5 
 
In both cases, 8g and 8h, mixtures of diastereoisomers were formed, which could be 
separated by column chromatography (SiO2, AcOEt/MeOH). The pure epimers (R,S,S)-8g and 
(S,S,S)-8g were obtained in a 1.6:1 ratio8). As the starting dipeptide 11 is a racemate, the 
coupling of (R)-11 with 13 is obviously more efficient than that of (S)-11. A similar result 
was obtained in the case of 8h: the epimers (R,S)-8h and (S,S)-8h8) were obtained in a 2:1 
ratio. 
2.2. Conformation of the Pro-Peptide Bonds in the Pentapeptides in Solution. – 
Whereas in general the trans-conformation of the peptide bond is highly preferred, cis- and 
trans-conformations of Xaa-Pro peptide bonds show comparable thermodynamic stability. 
This was shown first for short peptides like (S-benzyl)-Cys-Pro-Leu-Gly-NH2 on the basis of 
7)  TBTU = O-(1H-Benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium tetrafluoroborate; 
HOBt = 1-hydroxybenzotriazole. 
8)  The configurations of (R,S,S)-8g and (R,S)-8h were established by X-ray crystallography 
(see chapter 2.3). 
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their 1H-NMR spectra [30]. Later, it has been demonstrated that 13C-NMR spectroscopy is a 
convenient method for distinguishing between the cis- and trans-conformation of the Xaa-Pro 
bond [31]. Typically, the chemical shifts of C(β)(Pro) and C(γ)(Pro) in cis-Xaa-Pro peptides 
are ca. 31.3 and 22.5 ppm, respectively, whereas the corresponding values for trans-Xaa-Pro 
peptides are 29.5 and 24.2 ppm [31c]. Obviously, the chemical shift difference, ∆δ,is 
a reliableindicatorfortheconformation, with values of ca. 8.8 for t  cis- and 5.3 ppm  
for the trans-conformation. For this reason, we analyzed the 13C-NMR spectra of the prepared 
Pro-containing pentapeptides 8d, (R,S,S)- and (S,S,S)-8g, (R,S)- and (S,S)-8h, and 10 (Table 
1). In all cases, only one conformation was observed with ∆δbetween 2.3 and 2.7 ppm, 
indicating the trans-conformation. This result corresponds with that of the crystal structure 
determination (chapter 2.3), i.e., the Xaa-Pro peptide bond adopts the same conformation in 
solution and in the crystal. 
 
 Table 1. 13C-NMR Chemical Shifts of C(β) and C(γ) of the Pro Residue in Pro-
Containing Pentapeptides 
 
2.3. Crystal Structures of Pentapeptides. – Suitable crystals of the tetrapeptide Z-Gly-
Aib-(R,S)-Phe(2Me)-Aib-N(Me)Ph (6a) were obtained from CH2Cl2/Et2O/hexane. The 
crystals are racemic and the asymmetric unit contains one peptide molecule plus one half of a 
disordered molecule of hexane, which sits across a centre of inversion. In Fig. 1, the peptide 
molecule with the (S)-configured amino acid Phe(2Me) is shown. The molecule forms a β-
turn of type III’ [33] with the Phe(2Me) unit in position (i+3) and an intramolecular H-bond 
N(4)–H….O(11) (H….O 2.13(3) Å, N….O 2.963(3) Å, N–H….O 169(3)°). This interaction has a 
graph set motif [34] of S(10). A second intramolecular H-bond is formed between N(10)–H 
and N(13). The other two NH groups are involved in intermolecular H-bonds with an adjacent 
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molecule (N(7)–H….O(2’), N(13)–H….O(5’)); these intermolecular interactions link the 
molecules into extended chains which run parallel to the [010] direction and can be described 
by graph set motifs of C(8) and C(11), respectively. 
 
Fig. 1. ORTEP Plot [32] of the molecular structure of the tetrapeptide 6a (50% 
probability ellipsoids, arbitrary numbering of atoms, H-atoms bonded to C-atoms omitted for 
clarity and only the major conformation of the disordered central benzyl ring is shown, 
solvent molecule not included) 
 
All peptide bonds show the trans-conformation, but the Phe(2Me)-Aib bond deviates 
significantly from planarity (ω = 155.5(2)°). The values of the torsion angles ω(Gly-Aib), 
 ω(Aib-Phe(2Me)), and ω(Aib-N(Me)Ph) are close to 180° (175.0(2), –176.6(2), and –
177.5(2)°). The torsion angles φ and ψ of Aib(2) (61.0(4) and 25.3(4)°) and Phe(2Me) 
(60.2(3) and 23.2(3)°) correspond well with the typical values of +60° and +30° for a left-
handed helical structure (β-turn of type III’) (e.g. [7][35]).  
The crystals of the pentapeptide Z-Gly-Aib-(R,S)-Phe(2Me)-Aib-Gly-OMe (8a), 
obtained from CH2Cl2/hexane, are also racemic. The extension of the peptide chain of 6a by 
an additional C-terminal Gly-OMe results in the formation of a 310-helix, i.e. three 
consecutive β-turns of type III/III’. The molecule containing (S)-Phe(2Me) again forms a left-
handed helix with β-turns of type III’ (Fig. 2, Table 2). Three intramolecular H-bonds 
stabilize the 310-helix: N(1)–H….O(8), N(4)–H….O(11), and N(7)–H….O(14) (Table 3). All 
these interactions form formal 10-membered rings (graph set motif S(10)), the last one 
involving the C=O group of the Z group. The other two NH groups (Gly(1) and Aib(2)) are 
involved in intermolecular H-bonds with the same O(5’)-atom of Phe(2Me) of an adjacent 
molecule. This O(5’)-atom, therefore, accepts two H-bonds, although one of these is quite 
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weak. The intermolecular H-bonds link the molecules into extended chains which run parallel 
to the [101] direction and can be described by graph set motifs of C(11) and C(8) for the 
interactions involving the donors Gly(1) and Aib(2), respectively. 
 
Fig. 2. ORTEP Plot [32] of the molecular structure of the pentapeptide 8a (50% 
probability ellipsoids, arbitrary numbering of atoms, H-atoms bonded to C-atoms omitted for 
clarity) 
 
Table 2. Torsion Angles ω, φ, and ψ of the Backbone of the Pentapeptides 6a, 8a, 
(S,S)-8e, 8f, (R,S,S)-8g, (R,S)-8h, and 10 in the Crystal (Amino Acid (i) = Gly(1))  
 
Table 3.  Intramolecular H-Bonds of Compounds 8a, (S,S)-8e, 8f, (R,S,S)-8g, (R,S)-8h, 
and 10 (atom numbering refers to Figs. 1 – 7) 
 
Racemic crystals of Z-Gly-(R,S)-Phe(2Me)-Gly-Aib-Aib-N(Me)Ph (8f) were grown 
from AcOEt/hexane. In Fig. 3, the molecule containing (S)-Phe(2Me) is depicted. The 
asymmetric unit contains one molecule of 8f and approximately one third of a highly 
disordered hexane molecule, which sits across a centre of inversion. Four of the five NH 
groups act as donors for H-bonds. Two of them, N(1)–H and N(4)–H, form intramolecular H-
bonds with amide O-atoms that are seven atoms along the peptide backbone to give a graph 
set motif of S(10) in each case (Table 3). These interactions form two β-turns of type III’ 
(Table 2), leading to a left-handed helical structure for the molecule containing (S)-Phe(2Me). 
Surprisingly, Gly(3) does not continue this helical structure, and the Z group is turned away 
from the helix. Rather N(7)–H of Gly(3) forms an intermolecular H-bond with the terminal 
amide O(24) of a neighboring molecule. The N(13)–H group of Gly(1) forms an 
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intermolecular H-bond to O(2) of the same neighboring molecule. These intermolecular 
interactions link the peptide molecules into extended chains, which run parallel to the [010] 
direction (graph set motifs C(11) and C(14), resp.). Interestingly, N(10)–H is not involved in 
any H-bonding. Finally, N(1)–H, N(4)–H, N(7)–H, and N(10)–H exhibit the usual weak 
‘sideways’ contacts with one of their neighboring N-atoms. All peptide bonds are in the trans-
conformation and differ only slightly from planarity, but the terminal amide group deviates 
significantly from planarity (torsion angle ω –153.1(8)°; Table 2).  
 
Fig. 3. ORTEP Plot [32] of the molecular structure of the pentapeptide 8f (50% 
probability ellipsoids, arbitrary numbering of atoms, H-atoms bonded to C-atoms omitted for 
clarity, solvent molecule not included) 
 
The crystals of Z-Gly-(S)-Phe(2Me)-Gly-Aib-Phe-OMe ((S,S)-8e) are 
enantiomerically pure, however the absolute configuration of the molecule has not been 
determined. The enantiomer used in the refinement was based on the S-configuration at 
C(23), resulting from (S)-configured H-Phe-OMe used in the synthesis. Based on this, the 
configuration at C(9) of Phe(2Me) is also S (Fig. 4). The Ph ring of the terminal benzyl group 
is disordered over two orientations, with a ratio of the conformers of 0.33:0.67. The crystal 
lattice also contains one disordered H2O molecule per peptide molecule. All five peptide NH 
groups act as donors for H-bonding. Two of the H-bonds are intramolecular interactions with, 
in each case, the amide O-atom two peptide units further along the peptide chain, forming two 
consecutive βturns of type III’ (graph set motif: S(10); Table 3). As a result of the presence 
of (S)-Phe(2Me), a left-handed helical structure is formed (see e.g., [36]). The presence of (S)-
Phe, an amino acid which usually forms right-handed helices, probably has no influence 
because of its position at the C-terminus of the peptide. As in 8f, the helix is not continued by 
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Gly(3), and the Z group is turned away. The NH group of Gly(3) forms an intermolecular H-
bond with O(2’) of Aib(4) of an adjacent molecule. A second intermolecular H-bond, N(13)–
H….O(5’), is formed with the same neighboring molecule. These two interactions link the 
peptide molecules into extended chains, which run parallel to the [100] direction (graph set 
motifs C(8) and C(11), resp.). The fifth interaction, from N(10)–H of Phe(2Me), involves a 
H2O molecule acting as an acceptor. Furthermore, analogous to 8f, N(1)–H, N(4)–H, N(7)–H, 
and N(10)–H are close enough to adjacent N-atoms in the peptide chain to form weak 
interactions. 
 
Fig. 4. ORTEP Plot [32] of the molecular structure of the pentapeptide (S,S)-8e (50% 
probability ellipsoids, arbitrary numbering of atoms, H-atoms bonded to C-atoms omitted for 
clarity and only the major conformation of the disordered terminal benzyl group is shown, 
water molecules not included) 
 
The asymmetric unit of Z-Gly-(R)-Phe(2Me)-Pro-Aib-Phe-OMe ((R,S,S)-8g) contains 
one peptide molecule, one molecule of AcOEt, and one site for a H2O molecule, which is 
partially occupied (50%). The crystals are enantiomerically pure, however the absolute 
configuration of the molecule has not been determined. The enantiomer used in the 
refinement was based on the known S configuration at C(6) and C(23) of the Pro and Phe 
residues, respectively. Based on this assumption, C(9) of Phe(2Me) has the R configuration. 
The molecule forms a right-handed 310-helix, as expected for a peptide containing two protein 
amino acids and (R)-Phe(2Me) (Fig. 1, Table 2). Again, the Z-group is turned away from the 
helix, in this case because of the presence of Pro in position 3 of the peptide. The N(1)–H and 
N(4)–H groups of Phe(5) and Aib(4), respectively, from intramolecular H-bonds with amide 
O-atoms that are seven atoms along the peptide backbone (graph set motif S(10) for each 
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interaction, Table 3). The NH groups of Phe(2Me)(2) and Gly(1), N(10)–H and N(13)–H, 
respectively, form intermolecular H-bonds with the amide O-atoms, O(5’) and O(2”), 
respectively, of different neighboring molecules. The N(10)–H interaction links the molecules 
into extended chains, which run parallel to the [100] direction (graph set motif C(8)), while 
the N(13)–H interaction links the molecules into a second type of extended chains, which also 
run parallel to the [100] direction (graph set motif C(14)). The H2O molecule acts as a donor 
for two H-bonds to amide O-atoms of two different peptide molecules (graph set motif D for 
each interaction). As a result, the amide O-atoms O(2) of Aib(4) and O(11) of Gly(1) are each 
acceptors of two H-bonds. Neither the H2O molecule nor the AcOEt molecule acts as an 
acceptor for H-bonds. The combination of all intermolecular interactions links the molecules 
into extended sheets, which lie parallel to the (010) plane. Finally, N(1)–H and N(4)–H 
exhibit the usual weak ‘sideways’ contacts with one of their neighboring N-atoms. 
 
Fig. 5. ORTEP Plot [32] of the molecular structure of the pentapeptide (R,S,S)-8g 
(50% probability ellipsoids, arbitrary numbering of atoms, H-atoms bonded to C-atoms 
omitted for clarity, solvent molecules not included) 
 
The crystals of Z-Gly-(R)-Phe(2Me)-Pro-Aib-Aib-N(Me)Ph (RS-8h) are 
enantiomerically pure, however the absolute configuration of the molecule has not been 
determined. The enantiomer used in the refinement was based on the known S configuration 
of the Pro residue (C(6)). The configuration of Phe(2Me), at (C(9)), is therefore R (Fig. 6). 
The asymmetric unit contains two independent peptide molecules, one hexane molecule, and 
a H2O molecule, which lies on a twofold axis. The two peptide molecules have generally 
similar conformations with the major difference being in the orientation of the Ph rings at 
each end of the peptide chain. One of the peptide molecules (molecule B) has disorder in the 
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Ph ring of the protecting group Z. In molecule A, the NH groups of the two Aib units, N(1)–H 
and N(4)–H, form intramolecular H-bonds with O(8) of Phe(2Me) and O(11) of Gly, 
respectively, resulting in two β-turns of type III (graph set motifs of S(10), Table 3). The 
same interactions occur in molecule B, involving N(51)–H and N(54)–H. These are the 
normal intramolecular interactions found for peptides of this type and help to form a right-
handed 310-helical structure (Table 2). These NH groups also have weak ‘sideways’ 
interactions with the next neighboring N-atom in the chain. The other NH groups and the H2O 
molecule act as donors for intermolecular H-bonds: N(10)–H in molecule A forms an H-bond 
with the amide O-atom, O(74), at the opposite end of molecule B. The corresponding group, 
N(60)–H, in molecule B, however, interacts with a different O-atom in another molecule A, 
namely O(2). These two interactions form spiralling ….A….B….A….B…. chains of molecules 
which run parallel to the [001] direction and have a binary graph set motif of C2,2(25). 
Furthermore, N(13)–H of molecule A forms an intermolecular H-bond with the amide O-atom 
of Pro(3), O(55), of molecule B and the same interaction, involving N(63)–H, occurs to link 
molecule B to atom O(5) of a different molecule A, thus forming extended ….A….B….A….B…. 
chains of molecules, which run parallel to the [010] direction (graph set motif C2,2(22)). The 
H2O molecule sits on a two-fold axis and therefore acts as a donor for two equivalent H-bonds 
to the amide O-atom O(52) of Aib(4) in two different B molecules (graph set motif D). The 
combination of the intermolecular interactions links the molecules into three-dimensional 
supramolecular frameworks. 
 
Fig. 6. ORTEP Plot [32] of the molecular structure of one of the two symmetry-
independent molecules of the pentapeptide (R,S)-8h (50% probability ellipsoids, arbitrary 
numbering of atoms, H-atoms bonded to C-atoms omitted for clarity, solvent molecules not 
included) 
14 
 
 
The crystals of Z-Gly-Aib-Pro-Aib-Aib-OH (10)  are enantiomerically pure, however 
the absolute configuration has not been determined. The enantiomer used in the refinement 
was based on the known S configuration of Pro (C(6)). The asymmetric unit contains one 
peptide and one disordered MeOH molecule. Two intramolecular H-bonds, N(1)–H….O(8) 
and N(4)–H….O(11), form two β-turns of type III (graph set motif S(10), Table 3), i.e., a right-
handed 310-helix, as expected for a peptide containing (S)-Pro as the only chiral amino acid. 
The other two NH groups, N(10)–H and N(13)–H, as well as the carboxyl OH group, O(25)–
H, form intermolecular H-bonds with carbonyl O-atoms in three different neighboring 
molecules. The O(25)–H….O(5’) interaction links the molecules into extended chains which 
run parallel to the [100] direction and have a graph set motif C(10)). The N(10)–H….O(2”) 
interaction links the molecules into extended chains which run parallel to the [010] direction 
(graph set motif C(11)), while the N(13)–H….O(8’’’) interaction links the molecules into 
extended chains which also run parallel to the [100] direction (graph set motif C(8)). The 
combination of these intermolecular interactions links the molecules into a two-dimensional 
network, which lies parallel to the (001) plane. The O(8)-atom acts as an acceptor for two H-
bonds, an intra- and an intermolecular one. Both positions for the disordered MeOH molecule 
indicate the presence of a H-bond to the carbonyl O(14)-atom. 
 
Fig. 7. ORTEP Plot [32] of the molecular structure of the pentapeptide 10 (50% 
probability ellipsoids, arbitrary numbering of atoms, H-atoms bonded to C-atoms omitted for 
clarity, solvent molecule not included) 
 
3. Conclusions. – The present results prove once more the usefulness of the 
‘azirine/oxazolone method’, combined with traditional segment coupling, in the synthesis of 
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peptides containing α,α-disubstituted α-amino acids. All of the Aib and Phe(2Me) residues, 
as well as the 1-aminocyclobutane carboxylic acid, have been added to N-protected amino 
acids or peptides via the reaction with the corresponding 2,2-disubstituted 2H-azirin-3-amine 
1. As shown in previous studies [7][8][25][37], the coupling of two α,α-disubstituted α-
amino acids does not suffer from steric hindrance. This is of importance because coupling 
reactions with N-terminal Aib residues are known to be difficult (see e.g. [38]). As the 
synthon for Phe(2Me), 1b, was used as a racemate2), racemic pentapeptides such as 8a or 
mixtures of epimers such as 8b were formed. The pure epimers were obtained after 
chromatographic separation in the cases of 8e, 8g, and 8h. 
It is also important to note that the segment coupling with dipeptides with a C-terminal 
Aib or Phe(2Me) residue could be performed in good yields, even in the case of tripeptides 9 
and 13 with a N-terminal Pro. Surprisingly, the coupling with TBTU/HOBt yielded the 
pentapeptides 8g and 8h in significantly higher yield than with PyBOP, which was the 
preferred coupling reagent in the cases without Pro. 
The X-ray crystal-structure determinations showed that all of the prepared 
pentapeptides adopt a 310-helical conformation, as expected for Aib-containing peptides [39]. 
As Aib is achiral, the handedness of the helix is determined by the chiral amino acid present. 
It has been shown that a right-handed helix is preferred when the poly-Aib peptide contains a 
N-terminal L-amino acid or a L-amino acid within the peptide chain [40]. On the other hand, a 
C-terminal L-amino acid leads to the inverse relationship, i.e., a left-handed helix. 
Furthermore, it was found that the chiral α,α-disubstituted α-amino acid Phe(2Me) has the 
opposite effect, i.e., an internal L-Phe(2Me) residue induces a left-handed helix [36a][41]. 
Recently, a similar reversal of the screw-sense induction was described for the amino acids 
Val and Val(2Me): the hexapeptides Ac-L-Xaa-(Aib)4-Gly NH2 and pentapeptides Ac-L-Xaa-
(Aib)4-OR form left-handed helices with Xaa = Val but right-handed helices with Xaa = 
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Val(2Me) [42]. The study of the influence of the type and the position of L- and D-amino 
acids on the helical screw sense of Aib-containing peptides is a topic of current interest (see, 
e.g., [43]). 
The crystal structures of the prepared pentapeptides are in full accordance with the 
results reported in [36][41]. Whereas the peptide 10 with (S)-Pro as the only chiral amino acid 
adopts a right-handed 310-helical structure, as is ‘normal’ for protein amino acids, the 
enantiomers of the racemic peptides 8a and 8f, containing (S)-Phe(2Me) in position 3 and 2, 
respectively, exist in a left-handed 310-helical conformation in the crystal.  Furthermore, in the 
crystal of the racemic tetrapeptide 6a, the enantiomer with (S)-Phe(2Me) forms a β-turn of 
type III’, i.e., a turn with a left-handed helical structure. On the other hand, both (R,S,S)-8g 
and (R,S)-8h form right-handed 310-helices, supported by the presence of (R)-Phe(2Me) as 
well as (S)-Pro in position 3.  
It is worth mentioning that in 8a three intramolecular (1←4) H-bonds are formed, 
stabilizing the 310 helix (Table 3). One of them is the interaction of N(7)–H of Phe(2Me) with 
C=O(14) of the Z protecting group. Surprisingly, only two intramolecular (1←4) H-bonds are 
present in the analogous pentapeptide 8f, and the Z group is not involved in an intramolecular 
H-bond. The analogous H-bond pattern with only two (1←4) interactions, is observed in the 
enantiomerically pure (S,S)-8e. In both cases, N(7)–H of Gly(3) does not form intramolecular 
H-bonds. In the two remaining pentapeptides (R,S,S)-8g and (R,S)-8h, which possess a Pro(3) 
unit, only two intramolecular (1←4) H-bonds, N(1)–H….O(8) and N(4)–H….O(11), are 
possible. 
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Experimental part 
 
1. Abbreviations. Acb, 1-aminocyclobutane carboxylic acid; Aib, 2-aminoisobutyric 
acid (2-methylalanin); CSA, camphor-10-sulfonic acid; DCC, N,N’-
dicyclohexylcarbodiimide; DEPC, diethyl cyanophosphonate; DIEA, ethyl(diisopropyl)amine 
(Hünig base); DPPA, diphenyl phosphorazidate; HBPyU, O-[(benzotriazol-1-
yl)oxy]dipyrrolidinocarbenium hexafluorophosphate; HOBt, 1-hydroxybenzotriazole; PyBOP 
= [(benzotriazol-1-yl)oxy]tripyrrolidinophosphonium hexafluorophosphate; TBTU, O-(1H-
benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; TFA, trifluoroacetic acid; 
Z, benzyloxycarbonyl. 
2. General. See [11][25]. Amino acids were purchased from Novabiochem and 
Bachem and are all L-configured, other reagents and solvents from Aldrich, Bachem, Fluka 
and Merck, resp. Solvents were purified by standard procedures. TLC: Merck TLC glass 
plates, silica gel 60 F254. Preparative layer chromatography (PLC): Merck glass plates, silica 
gel 60 F254. Column chromatography (CC): Uetikon-Chemie, silica gel C-560 (0.04-0.063 
mm). M.p. were measured on a Mettler-FP-5 apparatus, uncorrected. [α]D-Values were 
determined on a Perkin-Elmer-241 polarimeter at 21°. IR Spectra were recorded on a Perkin-
Elmer-781 spectrometer, in KBr. 1H-NMR and 13C-NMR spectra were recorded on a Bruker 
AC-300 or Bruker ARX-300 spectrometer at 300 (1H) and 75.5 MHz (13C), respectively, in 
CDCl3, CD3OD or (D6)DMSO. The multiplicity of 13C signals was determined by the DEPT 
technique. ESI-MS were measured on a Finnigan TSQ-700 instrument, and CI-MS (with NH3 
or isobutane) on a Finnigan MAT-90 or SSQ-700 instrument; m/z (rel. %).  
General Procedure 1 (GP 1, Coupling with 2H-Azirin-3-amines). To a soln. of an N-
protected amino acid or N-protected peptide (1 mmol) in abs. THF (5 ml) at 0°, 1.1 equiv. of 
the corresponding 2H-azirin-3-amine in THF were added, and the mixture was stirred at r.t. 
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for several h (Ar atmosphere). After completion of the reaction, the solvent was evaporated 
and the product was purified by crystallization from CH2Cl2/hexane or AcOEt/hexane. In the 
case of incomplete reactions, the residue was dissolved in CH2Cl2, the remaining acid 
extracted with 1N aq. NaOH, the solvent evaporated, and the residue crystallized. 
General Procedure 2 (GP 2, Selective Hydrolysis of Peptide N-Methyl-N-
phenylamides). A soln. of the peptide amide (1 mmol) in 3N HCl (THF/H2O (1:1); 10 ml) was 
stirred at r.t. for 1–60 h. Then, aq. 2N HCl was added, and the mixture was extracted with 
Et2O. The org. layers were combined, dried (Na2SO4), and the solvent evaporated.  
General Procedure 3 (GP 3, Hydrogenolytic Deprotection). The Z-protected peptide 
(1 mmol) was dissolved in MeOH, and 10 weight% Pd/C (10%) was added to the soln. The 
mixture was stirred at r.t. under an H2 atmosphere overnight. Then, the soln. was filtered 
through a pad of Celite and the solvent was evaporated. The product was dried in high 
vacuum (i.v.).   
General Procedure 4 (GP 4, Deprotection via Catalytic Hydrogen Transfer [44]). To a 
soln. of Z-protected peptide (1 mmol) in MeOH were added 10 weight% Pd/C (10%) and 
HCO2NH4 (5 mmol). The mixture was heated at reflux (10 min) and filtered through a pad of 
Celite, washed with MeOH, and the solvent was evaporated. 
General Procedure 5 (GP 5, Coupling of Amino Acids). To a soln. of a Z-protected 
peptide (1 mmol), an amino acid ester (1.1 mmol), and a coupling reagent (1 mmol) in 
CH2Cl2 (1 ml) was added drop-wise DIEA (2 mmol; 3 mmol by using the hydrochloride of 
the amino acid ester) at r.t. The soln. was stirred for 1 h, and then the solvent evaporated. The 
residue was dissolved in AcOEt (20 ml), washed with 5% aq. KHSO4 (3×), 5% aq. NaHCO3 
(3×), and sat. aq. NaCl soln.,  and purified by CC. 
3. Synthesis of the Pentapeptides 8. 3.1. Z-Gly-Aib-(R,S)-Phe(2Me)-Aib-Gly-OMe 
(8a). 3.1.1. Z-Gly-Aib-(R,S)-Phe(2Me)-N(Me)Ph (4a). According to GP 1, to a soln. of Z-Gly-
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Aib-OH (3) [25] (4.49 g, 15.3 mmol) in abs. THF (70 ml) at 0° was added 2-benzyl-2,N-
dimethyl-N-phenyl-2H-azirin-3-amine (1b; 15.1 g of a ca. 3:4 mixture of 1b and 2-benzyl-N-
methyl-N-phenylpropanamide (ca. 25.9 mmol 1b)); stirring at r.t. for 70 h. The solvent was 
evaporated and the product purified by CC (CH2Cl2/MeOH 97:3): 5.95 g (72%) of 4a. 
Colorless foam. M.p. 72.2–73.1°. IR (KBr): 3320m, 3060m, 3030m, 2980m, 2940m, 1640s, 
1590s, 1515s, 1495s, 1450s, 1380m, 1365m, 1260m, 1240m, 1190m, 1155m, 1105m, 1080m, 
1050m, 770m, 735m, 700s. 1H-NMR (CDCl3): 7.46 (s, NH); 7.4–7.2 (m, 11 arom. H); 7.15–
7.05 (m, 4 arom. H); 6.85 (s, NH); 5.62 (br. s, NH); 5.11 (s, PhCH2O); 3.77 (d, J = 5.4, 
CH2(Gly)); 3.48, 3.06 (AB, JAB = 14.2, PhCH2); 3.31 (s, MeN); 1.42 (s, Me2C); 1.33 (s, 
Me(Phe(2Me)). 13C-NMR (CDCl3): 172.6, 172.5, 168.1 (3s, 3 CO(amide)); 156.5 (s, 
CO(urethane)); 144.1, 136.4, 136.3 (3s, 3 arom. C); 129.8, 129.5, 128.5, 128.2, 128.1, 128.0, 
127.0 (7d, 15 arom. CH); 67.0 (t, PhCH2O); 63.2, 57.5 (2s, C(2)(Aib), C(2)(Phe(2Me))); 44.9 
(t, CH2(Gly)); 42.3 (t, PhCH2); 41.8 (q, MeN); 24.9, 24.6, 23.5 (3q, Me2C, Me(Ph(2Me))). CI-
MS: 545 (7, [M+1]+), 439 (13), 438 (53, [M–Ph(Me)N]+), 437 (100, [M–PhCH2O]+), 412 (8), 
411 (15).  Anal. calc. for C31H36N4O5 (544.65): C 68.36, H 6.66, N 10.29; found: C 67.96, H 
6.90, N 10.35. 
3.1.2. Z-Gly-Aib-(R,S)-Phe(2Me)-OH (5a). According to GP 2, a soln. of 4a (5.86 g, 
10.8 mmol) in 3N HCl was stirred at r.t. for 7 h. The solvent was evaporated and the 
precipitate was filtered: 4.50 g (92%) of 5a. Colorless crystals. M.p. 192.6–193.8°. IR (KBr): 
3310m, 3040m, 2980m, 2970m, 1720s, 1660s, 1650s, 1560m, 1525s, 1460m, 1450m, 1440m, 
1285m, 1275m, 1245s, 1195m, 1165m, 1130m, 700m. 1H-NMR ((D6)DMSO): 12.6 (br. s, 
COOH); 7.96 (s, NH); 7.49 (t, J = 5.8, NH(Gly)); 7.35–7.15 (m, 8 arom. H, NH); 7.1–7.05 (m, 
2 arom. H); 5.00 (s, PhCH2O); 3.58 (d, J = 6.0, CH2(Gly)); 3.17 (s, PhCH2); 1.39, 1.35, 1.30 
(3s, Me2C, Me(Phe(2Me))). 13C-NMR ((D6)DMSO): 175.2, 173.5, 169.0 (3s, 2 CO (amide), 
COOH); 156.8 (s, CO(urethane)); 137.4, 137.0 (2s, 2 arom. C); 130.7, 128.7, 128.1, 128.0, 
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126.8 (5d, 10 arom. CH); 65.8 (t, PhCH2O); 59.5, 56.6 (2s, C(2)(Aib), C(2)(Phe(2Me))); 44.2 
(t, CH2(Gly)); 41.0 (t, PhCH2); 25.4, 24.8, 22.7 (3q, Me2C, Me(Phe(2Me))). CI-MS: 457 (6), 
456 (24, [M+1]+), 439 (28), 438 (100, [M–H2O+1]+), 348 (12), 330 (8), 312 (12), 295 (47), 
277 (15, [M–Phe(2Me)]+, 251 (18), 180 (30), 134 (26).  Anal. calc. for C24H29N3O6 (455.51): 
C 63.28, H 6.42, N 9.22; found: C 62.99, H 6.31, N 9.05. 
3.1.3. Z-Gly-Aib-(R,S)-Phe(2Me)-Aib-N(Me)Ph (6a). According to GP 1, 5a (931 mg, 
2.04 mmol) was reacted with 2,2,N-trimethyl-N-phenyl-2H-azirin-3-amine (1a [26]; 395 mg, 
2.27 mmol) in THF/DMF (20:1; 21 ml) for ca. 70 h: 1.21 g (94%) of 6a. Colorless crystals. 
M.p. 91.3–93.0°. IR (KBr): 3420m, 3320m, 3280m, 1720s, 1680s, 1650s, 1635s, 1590m, 
1530s, 1495s, 1455m, 1395m, 1380m, 1365m, 1280m, 1240s, 1215m,1195m, 1170m, 1100m,  
1090m, 1050m, 740m, 705s. 1H-NMR (CDCl3): 7.66 (s, NH); 7.35–7.15 (m, 13 arom. H); 
7.1–7.05 (m, 2 arom. H); 6.87, 6.56, 6.18 (3s, 3 NH); 5.03, 4.98 (AB, JAB = 12.2, PhCH2O); 
3.65–3.55 (m, CH2(Gly), 1H of PhCH2); 3.35 (s, MeN); 3.09 (d, JAB = 13.7, 1H of PhCH2); 
1.46 (s, Me2C); 1.42, 1.38, 1.27 (3s, Me2C, Me(Phe(2Me))). 13C-NMR (CDCl3): 174.0, 173.5, 
172.9, 170.3 (4s, 4 CO(amide)); 157.1 (s, CO(urethane)); 145.6, 136.8, 136.2 (3s, 3 arom. C); 
130.9, 129.2, 128.5, 128.2, 128.0, 127.9, 127.5, 127.0, 126.7 (9d, 15 arom. CH); 67.0 (t, 
PhCH2O); 60.2, 57.6, 57.2 (3s, 2 C(2)(Aib), C(2)(Phe(2Me))); 45.3 (t, CH2(Gly)); 40.5 (q, 
MeN); 40.3 (t, PhCH2); 25.8, 25.5, 24.3 (3q, 2 Me2C, Me(Phe(2Me))). ESI-MS: 668 (29, 
[M+K]+, 652 (100, [M+Na]+, 523 (47, [M–N(Me)Ph]+).  Anal. calc. for C35H43N5O6 (629.76): 
C 66.75, H 6.88, N 11.12; found: C 66.55, H 6.67, N 11.00. 
Suitable crystals for the X-ray crystal-structure determination were grown from 
CH2Cl2/Et2O/hexane by slow evaporation of the solvent. 
3.1.4. Z-Gly-Aib-(R,S)-Phe(2Me)-Aib-OH (7a). According to GP 2, 6a (4.12 g, 6.55 
mmol) was hydrolyzed for 3.5 h: 3.21 g (91%) of 7a. Colorless solid. M.p. 193.5–195.7°. IR 
(KBr): 3400m, 3300m, 2980m, 1760s, 1680s, 1650s, 1530s, 1500m, 1470m, 1455m, 1390m, 
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1315m, 1280m, 1240m, 1160m, 700m. 1H-NMR ((D6)DMSO): 8.27 (s, NH); 7.51 (t, J = 5.5, 
NH(Gly)); 7.47 (s, NH); 7.4–7.2 (m, 8 arom. H); 7.15–7.1 (m, 2 arom. H); 6.97 (s, NH); 5.01, 
4.98 (AB, JAB = 13.4, PhCH2O); 3.7–3.5 (ABX, JAB = 16.3, CH2(Gly)); 3.40, 2.99 (AB, JAB = 
13.4, PhCH2); 1.36, 1.35, 1.33, 1.30, 1.22 (5s, 2 Me2C, Me(Phe(2Me))). 13C-NMR (CDCl3): 
175.5, 172.82, 172.78, 169.9 (4s, 3 CO(amide), COOH); 156.6 (s, CO(urethane)); 137.0, 
136.7 (2s, 2 arom. C); 130.7, 128.2, 127.73, 127.68, 127.5, 126.1 (6d, 10 arom. CH); 65.6 (t, 
PhCH2O); 58.7, 56.1, 54.7 (3s, 2 C(2)(Aib), C(2)(Phe(2Me))); 43.6 (t, CH2(Gly)); 39.2 (t, 
PhCH2); 25.6, 24.9, 24.3, 24.2, 23.2 (5q, 2 Me2C, Me(Phe(2Me))). ESI-MS: 563 (100, 
[M+Na]+).  Anal. calc. for C28H36N4O7 (540.62): C 62.21, H 6.71, N 10.36; found: C 62.15, H 
6.70, N 10.34. 
3.1.5. Z-Gly-Aib-(R,S)-Phe(2Me)-Aib-Gly-OMe (8a). According to GP 5, 7a (2.46 g, 
4.54 mmol) was coupled with H-Gly-OMe.HCl (639 mg, 5.09 mmol) by treatment with 
PyBOP (2.22 g, 4.63 mmol) and DIEA (1.81 g, 13.97 mmol) in CH2Cl2 (7 ml); 1 h. CC with 
AcOEt gave 2.54 g (91%) 8a. Colorless foam. M.p. 160.3–161.3°. IR (KBr): 3340m, 3320s, 
3000s, 2960m, 1755s, 1705s, 1675s, 1650s, 1530s, 1460m, 1385m, 1365m, 1305m, 1290m, 
1260m, 1240m, 1215m, 1195m, 1180m, 1160m, 975m, 740m, 710m, 700m. 1H-NMR (CDCl3): 
7.81 (t, NH(Gly)); 7.41 (s, NH);  7.35–7.2 (m, 8 arom. H); 7.1–7.05 (m, 2 arom. H); 6.90, 6.82 
(2s, 2 NH); 6.08 (t-like, NH(Gly)); 4.97 (s, PhCH2O); 3.95 (d, J = 5.9, CH2(Gly)); 3.71–3.70 
(m, CH2(Gly)); 3.56 (s, MeO); 3.23, 3.03 (AB, JAB = 13.7, PhCH2); 1.49, 1.46, 1.39, 1.37 (4s, 
2 Me2C, Me(Phe(2Me))). 13C-NMR (CDCl3): 176.2, 174.8, 173.8, 171.5, 170.5 (5s, 4 
CO(amide), COOMe); 157.3 (s, CO(urethane)); 136.1, 136.0 (2s, 2 arom. C); 130.8, 128.6, 
128.3, 128.1, 127.9, 127.0 (6d, 10 arom. CH); 67.1 (t, PhCH2O); 59.9, 57.3, 57.0 (3s, 2 
C(2)(Aib), C(2)(Phe(2Me))); 52.2 (s, MeO); 45.4, 41.4, 41.1 (3t, 2 CH2(Gly), PhCH2); 26.2, 
25.4, 24.5, 23.4 (4q, 2 Me2C, Me(Phe(2Me))). ESI-MS: 650 (5, [M+K]+), 634 (100, 
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[M+Na]+], 612 (3, [M+1]+). Anal. calc. for C31H41N5O8 (611.69): C 60.87, H 6.76, N 11.45; 
found: C 60.78, H 6.63, N 11.44. 
Suitable crystals for the X-ray crystal-structure determination were grown from 
CH2Cl2/hexane by slow evaporation of the solvent. 
3.2. Z-Gly-Aib-(R,S)-Phe(2Me)-Aib-Phe-OBn (8b). According to GP 5, 7a (432 mg, 
0.779 mmol) was coupled with H-Phe-OBn.HCl (250 mg, 0.857 mmol) by treatment with 
PyBOP (373 mg, 0.779 mmol) and DIEA (307 mg, 2.205 mmol) in CH2Cl2 (3 ml); 5.5 h. CC 
with AcOEt/hexane 3:1 gave 527 mg (85%) 8b (mixture of diastereoisomers). Colorless solid. 
M.p. 134.0–136.5°. [α]D = –20.3 (c = 0.5, EtOH). IR (KBr): 3300m, 1740m, 1700m, 1660s, 
1535s, 1500m, 1455m, 1275m, 1240m, 700m. 1H-NMR (CDCl3): 7.78 (m, NH); 7.46, 7.36 
(2s, 1 NH); 7.25–7.15 (m, 18 arom. H); 7.1–7.05 (m, 2 arom. H); 6.69, 6.93 (2s, 1 NH); 6.75, 
6.71 (2s, 1 NH); 6.22, 6.17 (2 br. s, 1 NH); 5.01 (s, PhCH2O); 5.0–4.9 (m, PhCH2O); 4.75–
4.65 (m, CH(Phe)); 3.65–3.6 (m, CH2(Gly)); 3.37, 3.2–3.1, 3.02 (t,m,d, J = 15.6, 13.7, 1:2:1, 2 
PhCH2); 1.46, 1.44, 1.40, 1.37, 1.34, 1.33 (6s, 2 Me2C; Me(Phe(2Me))). 13C-NMR (CDCl3): 
175.7, 174.1, 173.0, 172.1, 170.3 (5s, 4 CO(amide), COOBn); 157.3 (s, CO(urethane)); 137.1, 
136.1, 135.5 (3s, 3 arom. C); 130.9, 129.3, 129.2, 128.5, 128.4, 128.3, 128.12, 128.09, 128.0, 
126.9, 126.6 (11d, 20 arom. CH); 67.1, 66.8, 66.7 (3t, 2 PhCH2O); 59.9, 57.0 (2s, 2 
C(2)(Aib), C(2)(Phe(2Me))); 54.5 (d, CH(2)Phe); 45.4, 37.5 (2t, CH2(Gly), 2 PhCH2); 25.7, 
25.0, 24.5, 24.1, 23.4 (5q, 2 Me2C, Me(Phe(2Me))). ESI-MS: 801 (100, [M+Na]+). Anal. calc. 
for C44H51N5O8 (777.92): C 67.94, H 6.61, N 9.00; found: C 67.79, H 6.88, N 9.00. 
3.3. Z-Gly-Aib-Acb-Aib-Gly-OMe (8c). 3.3.1. Z-Gly-Aib-Acb-NMe2 (4b). According to 
GP 1, 3 (1.68 g, 5.72 mmol) was reacted with 2-dimethylamino-1-azabicyclo[2.3]hex-1-ene 
(1c) [2b] (782 mg, 6.30 mmol) in THF (16 ml); ca. 1 h. The precipitate was filtered and 
washed with Et2O: 1.02 g of 8c. CC (CH2Cl2/MeOH 10:1) of the filtrate gave another 1.06 g 
of 8c. Total yield: 2.08 g (87%). Colorless solid. M.p. 212.3–213.7°. IR (KBr): 3340m, 3270s, 
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3050m, 2980m, 2940m, 1730s, 1710m, 1680m, 1660s, 1630s, 1540m, 1530m, 1395m, 1270m, 
1245m, 1230m, 750w, 700w. 1H-NMR ((D6)DMSO): 7.90, 7.89 (2s, 2 NH); 7.56 (t-like, NH); 
7.35–7.3 (m, 5 arom. H); 5.05 (s, PhCH2O); 3.61 (d, J = 5.8, CH2(Gly)); 3.33 (s, Me2N); 2.6–
2.5, 2.2–2.1, 1.76–1.74, 1.6–1.55 (4m, 2:2:1:1, 3 CH2(Acb)); 1.36 (s, Me2C). 13C-NMR 
((D6)DMSO): 175.2, 170.6, 168.4 (3s, 3 CO(amide)); 156.6 (s, CO(urethane)); 136.9 (s, 1 
arom. C); 128.3, 127.7, 127.5 (3d, 5 arom. CH); 65.4 (t, PhCH2O); 58.2, 55.7 (2s, C(2)(Aib), 
C(2)(Acb)); 44.0 (t, CH2(Gly)); 36.8, 36.0 (2q, Me2N); 30.9 (t, 2 CH2(Acb)); 24.8 (q, Me2C), 
14.3 (t, CH2(Acb)). ESI-MS: 441 (100, [M+Na]+). 
3.3.2. Z-Gly-Aib-Acb-OH (5b). According to GP 2, 4b (372 mg, 0.890 mmol) was 
hydrolyzed  for 70 h at 40°: 334 mg (96%) of 5b. Colorless crystals. M.p. 180.5–182.3°. IR 
(KBr): 3340s, 3290s, 3060m, 2980m, 2950m, 1720s, 1680s, 1670s, 1650s, 1565m, 1550s, 
1540s, 1525m, 1470m, 1430s, 1385m, 1280s, 1250s, 1235m, 1165m, 1110m, 750m. 1H-NMR 
(CD3OD): 7.4–7.25 (m, 5 arom. H); 5.11 (s, PhCH2O); 3.72 (s, CH2(Gly)); 2.65–2.5, 2.4–2.3, 
2.05–1.85 (3m, 3 CH2(Acb)); 1.44 (s, Me2C). 13C-NMR (CD3OD): 175.5, 174.8, 170.1 (3s, 2 
CO(amide), COOH); 157.8 (s, CO(urethane)); 136.6 (s, 1 arom. C); 128.0, 127.5, 127.3 (3d, 5 
arom. CH); 66.3 (t, PhCH2O); 58.2, 56.2 (2s, C(2)(Aib), C(2)(Acb)); 44.0 (t, CH2(Gly)); 30.5 
(t, 2 CH2(Acb)); 23.8 (q, Me2C), 14.8 (t, CH2(Acb)). ESI-MS: 430 (51, [M+K]+), 414 (100, 
[M+Na]+). Anal. calc. for C19H25N3O6.0.5H2O (400.43): C 56.99, H 6.54, N 10.49; found: C 
57.25, H 6.77, N 10.76. 
3.3.3. Z-Gly-Aib-Acb-Aib-N(Me)Ph (6b). According to GP 1, 5b (840 mg, 2.15 mmol) 
was reacted with 1a (411 mg, 2.36 mmol) in THF/DMF (29 ml, 28:1). CC (CH2Cl2/MeOH 
10:1) gave 1.14 g (94%) of 6b. Colorless solid. Phase transitions at 137 and 167°; m.p. 187.8–
188.3°. IR (KBr): 3300s, 3060m, 2990m, 2940m, 1710s, 1680s, 1675s, 1670s, 1660s, 1650s, 
1645s, 1630s, 1605m, 1590m, 1550s, 1540s, 1530s, 1520s, 1505s, 1495s, 1470s, 1395m, 
1275m, 1265m, 1240s, 1190m, 1155m, 1090m, 700m. 1H-NMR (CD3OD): 7.51 (br. s, 2 NH); 
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7.4–7.2 (m, 10 arom. H); 6.58 (br. s, NH); 6.44 (s, NH); 5.15 (s, PhCH2O); 3.70 (d, J = 5.2, 
CH2(Gly)); 3.30 (s, MeN); 2.7–2.55, 2.15–1.95, 1.95–1.8 (3m, 2:3:1, 3 CH2(Acb)); 1.44, 1.28 
(2s, 2 Me2C). 13C-NMR (CDCl3): 174.0, 173.7, 173.5, 170.7 (4s, 4 CO(amide)); 157.6 (s, 
CO(urethane)); 146.0, 136.5 (2s, 2 arom. C); 129.2, 128.5, 128.2, 127.8, 127.3, 127.0 (6d, 10 
arom. CH); 67.0 (t, PhCH2O); 59.2, 56.8, 56.6 (3s, 2 C(2)(Aib), C(2)(Acb)); 45.7 (t, 
CH2(Gly)); 40.5 (q, MeN); 31.6, 31.3 (2t, 2 CH2(Acb)); 25.7, 24.9 (2q, 2 Me2C), 16.0 (t, 
CH2(Acb)). ESI-MS: 588 (100, [M+Na]+), 459 (5, [M– N(Me)Ph]+), 374 (26, [M–Aib-
N(Me)Ph]+), 277 (3, [M–Acb-Aib-N(Me)Ph)]+). 
3.3.4. Z-Gly-Aib-Acb-Aib-OH (7b). According to GP 2, 6b (1.033 g, 1.83 mmol) was 
hydrolyzed and the product extracted with AcOEt: 828 mg (95%) of 7b. Colorless solid. M.p. 
201.4–203.6°. IR (KBr): 3350m, 3320s, 3270s, 3000m, 2960m, 1730s, 1705s, 1670s, 1660s, 
1650s, 1635s, 1605m, 1545s, 1540s, 1530s, 1470m, 1465m, 1395m, 1330m, 1310m, 1290m, 
1260s, 1245s, 1215m, 1170m, 1150m, 970m, 745m. 1H-NMR (CD3OD): 8.40 (s, 0.3 NH); 
7.98 (s, NH); 7.34 (s, 0.7 NH); 7.4–7.25 (m, 10 arom. H); 5.08 (s, PhCH2O); 3.71 (s, 
CH2(Gly)); 2.7–2.6, 2.25–2.1, 2.0–1.9 (3m, 2 H each, 3 CH2(Acb); 1.47, 1.44 (2s, 2 Me2C). 
13C-NMR (CD3OD): 178.2, 176.3, 175.3, 172.5 (4s, 3 CO(amide), COOH); 159.5 (s, 
CO(urethane)); 138.1 (s, 1 arom. C); 129.5, 129.1, 128.9 (3d, 5 arom. CH); 68.1 (t, PhCH2O); 
60.5, 57.7, 57.1 (3s, 2 C(2)(Aib), C(2)(Acb)); 45.3 (t, CH2(Gly)); 31.9 (t, 2 CH2(Acb)); 25.4 
(q, 2 Me2C); 16.5 (t, CH2(Acb)). ESI-MS: 499 (100, [M+Na]+). Anal. calc. for C23H32N4O7 
(476.53): C 57.97, H 6.77, N 11.76; found: C 57.76, H 6.84, N 11.31. 
3.3.5. Z-Gly-Aib-Acb-Aib-Gly-OMe (8c). According to GP 5, 7b (268 mg, 0.653 
mmol) and H-Gly-OMe.HCl (79 mg, 0.629 mmol) were treated with HBPyU (243 mg, 0.564 
mmol) and DIEA (220 mg, 1.702 mmol) for 0.5 h. CC (AcOEt/MeOH 20:1) gave 255 mg 
(83%) of 8c. Colorless solid. M.p. 160.0–161.4°. IR (KBr): 3340s, 3280s, 3060m, 2980m, 
2950m, 1740s, 1710s, 1685s, 1650s, 1630s, 1550s, 1540s, 1530s, 1505m, 1470m, 1465m, 
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1455m, 1440m, 1380m, 1365m, 1310m, 1275s, 1240s, 1220m, 1195m, 1170m, 1155m, 1050m, 
700m. 1H-NMR (CDCl3): 7.52 (s, NH); 7.46 (t, J = 5.8, NH(Gly)); 7.4–7.35 (m, 5 arom. H, 1 
NH); 6.90 (s, NH); 6.31 (t-like, NH); 5.14 (s, PhCH2O); 3.98 (d, J = 5.8, CH2(Gly)); 3.75 (d, J 
= 5.2, CH2(Gly)); 3.65 (s, MeO); 2.75–2.7, 2.05–1.85 (2m, 1:2, 3 CH2(Acb); 1.55, 1.46 (2s, 2 
Me2C). 13C-NMR (CDCl3): 176.5, 175.3, 173.6, 171.0, 170.6 (5s, 4 CO(amide), COOMe); 
157.8 (s, CO(urethane)); 136.4 (s, 1 arom. C); 128.6, 128.2, 127.6 (3d, 5 arom. CH); 67.2 (t, 
PhCH2O); 59.2, 57.0, 56.6 (3s, 2 C(2)(Aib), C(2)(Acb)); 52.1 (q, MeO); 45.8, 41.4 (2t, 2 
CH2(Gly)); 30.9 (t, 2 CH2(Acb)); 25.3, 24.7 (2q, 2 Me2C); 15.4 (t, CH2(Acb)). ESI-MS: 570 
(100, [M+Na]+).  
3.4. Z-Gly-Aib-Pro-Aib-Aib-N(Me)Ph (8d). According to GP 5, 3 (1.18 g, 4.00 mmol) 
and H-Pro-Aib-Aib-N(Me)Ph [25b] (1.65 g, 4.40 mmol) in CH2Cl2 (20 ml) were treated with 
HBPyU (1.72 g, 4.00 mmol) and DIEA (1.03 g, 8.00 mmol) for 15 h. CC (CH2Cl2/MeOH 
20:1) gave 2.15 g (82%) of 8d. Colorless solid. M.p. 107.6–108.7°. [α]D = +34.5 (c = 1.04, 
EtOH). IR (KBr): 3420m, 3300s, 3060m, 2980m, 2930m, 1725s, 1660s, 1625s, 1595m, 1540s, 
1520s, 1495s, 1470m, 1455m, 1410m, 1395m, 1365m, 1280m, 1240s, 1215m, 1170m, 1090m, 
1050m, 705m, 700m. 1H-NMR (CDCl3): 7.57 (s, NH); 7.41 (s, NH); 7.4–7.15 (m, 10 arom. H, 
1 NH); 6.14 (br. s, NH); 5.10, 5.08 (AB, JAB = 12.0, PhCH2O); 4.2–4.15 (m, CH2(2)(Pro)); 
3.8–3.55 (m, CH2(Gly), 1 H of CH2(5)(Pro)); 3.38 (s, MeN); 3.35–3.2 (m, 1 H of 
CH2(5)(Pro)); 2.35–2.2, 1.95–1.8, 1.75–1.65 (3m, CH2(3), CH2(4)(Pro)); 1.60, 1.58, 1.49, 
1.43, 1.28 (5s, 1:1:1:2:1, 3 Me2C). 13C-NMR (CDCl3): 175.1, 174.3, 173.3, 171.7, 169.7 (5s, 5 
CO(amide)); 156.9 (s, CO(urethane)); 145.5, 136.5 (2s, 2 arom. C); 129.1, 128.5, 128.2, 
128.0, 127.2, 126.6 (6d, 10 arom. CH); 66.9 (t, PhCH2O); 64.2 (d, CH(2)(Pro)); 57.1, 57.0, 
56.5 (3s, 3 C(2)(Aib)); 48.7 (t, CH2(5)(Pro)); 44.1 (t, CH2(Gly)); 40.1 (s, MeN); 28.8, 26.2 
(2t, CH2(3), CH2(4)(Pro)); 27.8, 26.1, 25.8, 25.6, 23.9, 23.6 (6q, 3 Me2C). ESI-MS: 673 (100, 
[M+Na]+). 
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3.5. Z-Gly-Aib-Pro-Aib-Aib-OH (10). According to GP 2, 8d (1.03 g, 1.58 mmol) was 
hydrolyzed for 4.5 h. The precipitate was filtered (549 mg of 10) and the filtrate purified by 
CC (CH2Cl2/MeOH 10:1). Total yield of 10: 629 mg (70%). Colorless solid. M.p. 192.3–
193.6°. [α]D = +22.4 (c = 1.02, MeOH). IR (KBr): 3460m, 3400m, 3310s, 3290s, 3040m, 
2990m, 2940m, 1715s, 1665s, 1650s, 1600s, 1540s, 1520s, 1470m, 1450m, 1425m, 1410m, 
1365m, 1310m, 1290m, 1280m, 1250m, 1215m, 1170m, 695m. 1H-NMR ((D6)DMSO): 8.53 
(s, NH); 7.55–7.3 (m, 5 arom. H, 2 NH); 7.17 (s, NH); 5.04, 5.00 (AB, JAB = 12.6, PhCH2O); 
4.09 (t, J = 7.8, CH2(2)(Pro)); 3.85–3.7, 3.7–3.55, 3.55–3.54 (3m, 1:2:1, CH2(Gly), 
CH2(5)(Pro)); 2.15–2.0, 1.95–1.7, 1.65–1.45 (3m, 1:2:1, CH2(3), CH2(4)(Pro)); 1.37, 1.34, 
1.32, 1.29 (4s, 1:2:2:1, 3 Me2C). 13C-NMR ((D6)DMSO): 175.4, 173.4, 172.3, 171.1, 168.9 
(5s, 4 CO(amide), COOH); 156.5 (s, CO(urethane)); 136.9 (s, 1 arom. C); 128.2, 127.7, 127.6 
(3d, 5 arom. CH); 65.4 (t, PhCH2O); 62.8 (d, CH(2)(Pro)); 55.6, 54.6 (2s, 3 C(2)(Aib)); 47.8 
(t, CH2(5)(Pro)); 42.7 (t, CH2(Gly)); 28.2, 25.5 (2t, CH2(3), CH2(4)(Pro)); 25.9, 25.4, 24.9, 
24.1, 24.0, 23.9 (6q, 3 Me2C). ESI-MS: 584 (100, [M+Na]+). Anal. calc. for 
C27H39N5O8.1.5H2O (588.66): C 55.09,  H 7.19, N 11.90; found: C 54.99, H 7.23, N 11.88. 
Suitable crystals for the X-ray crystal-structure determination were grown from 
MeOH. 
3.6. Z-Gly-(R,S)-Phe(2Me)-Gly-Aib-Phe-OMe (8e). 3.6.1. Z-Gly-Aib-Phe-OMe. 
According to GP 5, a mixture of Z-Gly-Aib-OH (3) [25] (1.03 g, 3.51 mmol) and H-Phe-
OMe.HCl (834 mg, 3.87 mmol) in CH2Cl2 (5 ml) was treated with PyBOP (1.68 g, 3.52 
mmol) and DIEA (1.34 g, 10.65 mmol). CC (AcOEt/hexane 3:1) gave 1.36 g (85%) Z-Gly-
Aib-Phe-OMe. Colorless solid. M.p. 150–158.7°. [α]D = +6.6 (c = 1.01, EtOH). IR (KBr): 
3380m, 3260m, 3070m, 1745s, 1710s, 1680s, 1635s, 1555s, 1525m, 1380m, 1275m, 1250m, 
1215m, 1205m, 1180m, 1160m, 1110w, 1080w, 1030w, 695m. 1H-NMR (CDCl3): 7.35–7.2 
(m, 8 arom. H); 7.15–7.1 (m, 2 arom. H); 6.67 (br. d, J = 6.7, NH); 6.54, 5.37 (2br. s, 2 NH); 
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5.13 (s, PhCH2O); 4.9–4.8 (ABX, CH(2)(Phe)); 3.78 (d, J = 5.6, CH2(Gly)); 3.72 (s, MeO); 
3.2–3.05 (ABX, JAB = 13.9, PhCH2); 1.48 (s, Me2C). 13C-NMR (CDCl3): 173.7, 171.9, 168.6 
(3s, 2 CO(amide), COOMe); 156.7 (s, CO(urethane)); 136.1, 135.9 (2s, 2 arom. C); 129.3, 
128.52, 128.48, 128.2, 128.0, 127.0 (6d, 10 arom. CH); 67.2 (t, PhCH2O); 57.2 (s, C(2)(Aib)); 
53.4 (q, MeO); 52.3 (d, CH(2)(Phe)); 44.9 (t, CH2(Gly)); 37.7 (t, PhCH2); 25.0, 24.9 (2q, 
Me2C). ESI-MS: 478 (7, [M+Na]+).  Anal. calc. for C24H29N3O6 (455.50): C 63.29, H 6.42, N 
9.23; found: C 62.99, H 6.64, N 8.99. 
3.6.2. H-Gly-Aib-Phe-OMe (12). According to GP 3, Z-Gly-Aib-Phe-OMe (158.6 mg, 
0.348 mmol) was deprotected: 110 mg (98%) of 12. Colorless oil. IR (CDCl3): 3420m, 
3310m, 2930m, 1740m, 1685s, 1660s, 1635s, 1600m, 1540s, 1510s, 1495s, 1450m, 1435m, 
1385m, 1360m, 1330m, 1275m, 1175m, 690m. 1H-NMR (CDCl3): 7.64 (s, NH); 7.3–7.1 (m, 5 
arom. H, 1 NH); 4.9–4.8 (ABX, CH(2)(Phe)); 3.71 (s, MeO); 3.26 (s, CH2(Gly)); 3.2–3.05 
(ABX, JAB = 13.9, PhCH2); 1.51, 1.49 (2s, Me2C). 13C-NMR (CDCl3): 174.0, 172.8, 172.0 (3s, 
2 CO(amide), COOMe); 136.0 (s, 1 arom. C); 129.3, 128.3, 126.9 (3d, 5 arom. CH); 56.8 (s, 
C(2)(Aib)); 53.3 (d, CH(2)(Phe)); 52.2 (q, MeO); 44.9 (t, CH2(Gly)); 37.6 (t, PhCH2); 25.0 (q, 
Me2C). ESI-MS: 665 (46, [2M+Na]+), 643 (100 [2M+1]+), 633 (82, [2M-MeOH+Na]+), 611 
(26, [2M-OMe]+), 344 (88, [M+Na]+), 322 (21, [M+1]+).   
3.6.3. Z-Gly-(R,S)-Phe(2Me)-Gly-Aib-Phe-OMe (8e). According to GP 5, a mixture of 
Z-Gly-(R,S)-Phe(2Me)-OH (11) [25a] (734 mg, 1.98 mmol) and 12 (700 mg, 2.18 mmol) in 
CH2Cl2 (10 ml) was treated with PyBOP (949 mg, 1.98 mmol) and DIEA (533 mg, 4.12 
mmol). CC (2×, AcOEt/MeOH 20:1) and PLC (AcOEt/MeOH 10:1) gave 623 mg (S,S)-8e 
and 586 mg (R,S)-8e; total yield: 1.21 mg (91%). 
Z-Gly-(S)-Phe(2Me)-Gly-Aib-Phe-OMe ((S,S)-8e). Colorless solid. M.p. 162.5–164.1°. 
[α]D = –69.0 (c = 1.01, EtOH). IR (KBr): 3410m, 3280s, 1745s, 1730s, 1670s, 1660s, 1535s, 
1455m, 1385m, 1360m, 1325m, 1280m, 1230s, 1190m, 1185m, 1165m, 1150m, 1110w, 
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1080w, 700m. 1H-NMR (CDCl3): 7.4–7.05 (m, 15 arom. H, 3 NH); 6.49 (s, NH); 5.80 (t-like, 
NH); 5.05, 4.98 (AB, JAB = 12, PhCH2O); 4.8–4.7 (ABX, CH(2)(Phe)); 3.9–3.65 (m, 2 
CH2(Gly)); 3.60 (s, MeO); 3.29, 3.03 (AB, JAB = 13.6, PhCH2); 3.2–3.05 (m, PhCH2); 1.48, 
1.44, 1.40 (3s, Me2C, Me(Phe(2Me))). 13C-NMR (CDCl3): 175.3, 175.0, 173.2, 170.7, 170.0 
(5s, 4 CO(amide), COOMe); 157.3 (s, CO(urethane)); 136.8, 136.1, 135.3 (3s, 3 arom. C); 
130.5, 129.1, 128.6, 128.5, 128.4, 128.3, 128.0, 127.2, 126.8 (9d, 15 arom. CH); 67.3 (t, 
PhCH2O); 59.6, 57.0 (2s, C(2)(Aib), C(2)(Phe(2Me))); 54.1 (d, CH(2)(Phe)); 52.5 (q, MeO); 
45.4, 44.3 (2t, 2 CH2(Gly)); 36.9, 30.7 (2t, 2 PhCH2); 25.9, 24.3, 22.7 (3q, Me2C, 
Me(Phe(2Me))). ESI-MS: 696 (100, [M+Na]+).  Anal. calc. for C36H43N5O8.H2O (691.78): C 
62.50, H 6.56, N 10.12; found: C 62.43, H 6.30, N 10.07. 
Suitable crystals for the X-ray crystal-structure determination were grown from 
AcOEt/hexane by slow evaporation of the solvent. 
Z-Gly-(R)-Phe(2Me)-Gly-Aib-Phe-OMe ((R,S)-8e). Colorless solid. M.p. 116.4–
118.2°. [α]D = +67.5 (c = 1.05, EtOH). IR (KBr): 3380m, 3280s, 1730s, 1680s, 1670s, 1660s, 
1540s, 1530s, 1455m, 1440m, 1410m, 1390m, 1365m, 1345m, 1310m, 1275m, 1230m, 1195m, 
1175m, 1150m, 1120w, 1080w, 1045m, 700m. 1H-NMR (CDCl3): 8.35 (br. s, NH); 7.65 (s, 
NH); 7.42 (d, J = 7.9, NH); 7.4–7.05 (m, 15 arom. H); 7.00 (s, NH); 6.18 (br. s, NH); 5.12, 
5.00 (AB, JAB = 12.3, PhCH2O); 4.65–4.55 (m, CH(2)(Phe)); 4.0–3.6 (m, 2 CH2(Gly)); 3.47, 
3.10 (AB, JAB = 13.7, PhCH2); 3.24 (s, MeO); 3.25–2.95 (m, PhCH2); 1.43, 1.38, 1.26 (3s, 
Me2C, Me(Phe(2Me))). 13C-NMR (CDCl3): 176.9, 176.4, 172.3, 171.0, 169.9 (5s, 4 
CO(amide), COOMe); 157.0 (s, CO(urethane)); 136.7, 136.4, 136.2 (3s, 3 arom. C); 131.1, 
129.0, 128.5, 128.4, 128.2, 128.1, 126.8, 126.6 (8d, 15 arom. CH); 67.1 (t, PhCH2O); 59.4, 
57.0 (2s, C(2)(Aib), C(2)(Phe(2Me))); 54.1 (d, CH(2)(Phe)); 52.0 (q, MeO); 45.5, 44.3 (2t, 2 
CH2(Gly)); 39.5, 37.2 (2t, 2 PhCH2); 27.0, 23.5 (2q, 1:2, Me2C, Me(Phe(2Me))). ESI-MS: 696 
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(100, [M+Na]+).  Anal. calc. for C36H43N5O8 (673.76): C 64.18, H 6.43, N 10.39; found: C 
63.91, H 6.33, N 10.53. 
3.7. Z-Gly-(R,S)-Phe(2Me)-Gly-Aib-Aib-N(Me)Ph (8f). According to GP 5, a mixture 
of 11 (100 mg, 0.270 mmol) and H-Gly-Aib-Aib-N(Me)Ph [25a] (99 mg, 0.296 mmol) in 
CH2Cl2 (2 ml) was treated with PyBOP (129 mg, 0.270 mmol) and DIEA (85 mg, 0.658 
mmol): 152 mg (82%) of 8f. Colorless solid. M.p. 191.9–192.8°. IR (KBr): 3410m, 3300m, 
1725m, 1680s, 1665s, 1650s, 1640s, 1595m, 1535s, 1495m, 1455m, 1395m, 1375m, 1365m, 
1270m, 1250m, 1240m, 1095m, 710m. 1H-NMR (CDCl3): 7.86 (br. s, NH); 7.4–7.05 (m, 15 
arom. H, 2 NH); 6.83, 6.54 (2br. s, 2 NH); 5.08, 5.02 (AB, JAB = 12.2, PhCH2O); 3.8–3.6 (m, 
2 CH2(Gly)); 3.23 (s, MeN); 3.23, 2.98 (AB, JAB = 13.6, PhCH2); 1.49, 1.46, 1.27 (3s, 3:1:1, 2 
Me2C, Me(Phe(2Me))). 13C-NMR (CDCl3): 175.6, 175.2, 174.0, 170.8, 169.2 (5s, 5 
CO(amide)); 157.3 (s, CO(urethane)); 145.3, 136.2, 135.6 (3s, 3 arom. C); 130.5, 129.1, 
128.4, 128.2, 128.1, 127.9, 127.0, 126.9 (8d, 15 arom. CH); 67.0 (t, PhCH2O); 59.3, 57.1 (2s, 
2 C(2)(Aib), C(2)(Phe(2Me))); 45.4, 44.8, 40.7 (3t, 2 CH2(Gly), PhCH2); 40.3 (q, MeN); 
25.91, 25.88, 24.9, 22.7 (4q, 1:2:1:1, 2 Me2C, Me(Phe(2Me))). ESI-MS: 725 (8, [M+K]+), 709 
(100, [M+Na]+), 580 (5, [M–N(Me)Ph]+).  Anal. calc. for C37H46N6O7 (686.81): C 64.71, H 
6.75, N 12.24; found: C 64.90, H 6.89, N 12.40. 
Suitable crystals for the X-ray crystal-structure determination were grown from 
AcOEt/hexane by slow evaporation of the solvent. 
3.8. Z-Gly-(R,S)-Phe(2Me)-Pro-Aib-Phe-OMe (8g). 3.8.1. Z-Pro-Aib-Phe-OMe. 
According to GP 5, a mixture of Z-Pro-Aib-OH [25b] (1.14 g, 3.40 mmol) and H-Phe-
OMe.HCl (808 mg, 3.75 mmol) in CH2Cl2 (6 ml) was treated with PyBOP (1.63 g, 3.40 
mmol) and DIEA (1.32 g, 10.23 mmol). CC (AcOEt/hexane 3:1) gave 1.33 g (79%) Z-Pro-
Aib-Phe-OMe. Colorless solid. M.p. 169.7–170.4°. [α]D = –23.8 (c = 0.817, EtOH). IR (KBr): 
3380m, 3280m, 1745s, 1690s, 1665s, 1640s, 1550m, 1525m, 1455m, 1435s, 1355m, 1240m, 
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1215m, 1205m, 1180m, 1170m, 1120m, 700m. 1H-NMR (CDCl3): 7.35–7.1 (m, 10 arom. H, 
0.8 NH); 6.86 (br. s, NH); 6.40 (br. s, 0.2 NH); 5.2–5.1 (m, PhCH2O); 4.8–4.75, 4.25–4.2 (2m, 
CH(2)(Phe), CH(2)(Pro)); 3.68 (s, MeO); 3.6–3.4 (m, CH2(5)(Pro)); 3.2–3.0 (ABX, JAB = 13.9, 
PhCH2); 2.25–1.25 (m, CH2(3), CH2(4)(Pro)); 1.44, 1.26 (2br. s, Me2C). 13C-NMR (CDCl3): 
173.7, 171.9 (2s, 2 CO(amide), COOMe); 156.1 (s, CO(urethane)); 136.3 (s, 2 arom. C); 
129.2, 128.4, 128.3, 128.1, 127.8, 126.8 (6d, 10 arom. CH); 67.2 (t, PhCH2O); 61.0 (d, 
CH(2)(Pro)); 57.2 (s, C(2)(Aib)); 53.6 (d, CH(2)(Phe)); 52.0 (s, MeO); 47.0 (t, CH2(5)(Pro)); 
37.8 (t, PhCH2);  28.4, 24.8 (2t, CH2(3), CH2(4)(Pro)); 25.5, 24.8 (2q, Me2C). ESI-MS: 518 
(100, [M+Na]+).  Anal. calc. for C27H33N3O6 (495.57): C 65.44, H 6.71, N 8.48; found: C 
65.49, H 6.97, N 8.54. 
3.8.2. H-Pro-Aib-Phe-OMe (13). According to GP 3, Z-Pro-Aib-Phe-OMe (1.15 g, 
2.32 mmol) in MeOH (25 ml) in the presence of Pd/C (113 mg) was deprotected (2 h): 842 
mg (84%) 13. Colorless oil. [α]D = +3.6 (c = 1.24, CHCl3). IR (CHCl3): 3280m, 3020m, 
3000s, 2980m, 1740s, 1670s, 1510s, 1455m, 1440m, 1390m, 1360m, 1215m, 1180m, 850m, 
700m. 1H-NMR (CDCl3): 7.89 (s, NH); 7.41 (d, J = 7.5, NH); 7.3–7.15 (m, 5 arom. H); 4.8–
4.75, 3.7–3.65 (2m, CH(2)(Pro), CH(2)(Phe)); 3.69 (s, MeO); 3.2–2.9 (m, CH2(5)(Pro), 
PhCH2, NH(Pro)); 2.15–2.05, 1.9–1.85, 1.75–1.65 (3m, 1:1:2, CH2(3), CH2(4)(Pro)); 1.47, 
1.45 (2s, Me2C). 13C-NMR (CDCl3): 175.2, 174.2, 172.1 (3s, 2 CO(amide), COOMe); 136.3 
(s, 1 arom. C); 129.3, 128.4, 126.9 (3d, 5 arom. CH); 60.7 (d, CH(2)(Pro)); 56.9 (s, 
C(2)(Aib)); 53.5 (d, CH(2)(Phe)); 52.2 (s, MeO); 47.2 (t, CH2(5)(Pro)); 37.7 (t, PhCH2);  
30.6, 26.0 (2t, CH2(3), CH2(4)(Pro)); 25.2, 25.1 (2q, Me2C). CI-MS: 363 (21), 362 (100, 
[M+1]+).  
3.8.3. Z-Gly-(R,S)-Phe(2Me)-Pro-Aib-Phe-OMe (8g). According to GP 5, a mixture of 
11 (374.5 mg, 1.01 mmol) and 13 (400 mg, 1.11 mmol) in CH2Cl2 (10 ml) was treated with 
TBTU (326.2 mg, 1.02 mmol) and DIEA (301.8 mg, 2.34 mmol) for 16 h. CC (4×, 
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AcOEt/MeOH 20:1) gave 193.9 mg (S,S)-8g and 319.8 mg (R,S)-8g; total yield: 513.7 mg 
(71%). 
Z-Gly-(S)-Phe(2Me)-Pro-Aib-Phe-OMe ((S,S,S)-8g). Colorless lacquer. M.p. 59.1–
60.7°. [α]D = –17.6 (c = 1.03, EtOH). IR (KBr): 3300m, 2940m, 1745s, 1740s, 1730s, 1720s, 
1670s, 1660s, 1635s, 1625s, 1565m, 1540s, 1520s, 1505s, 1460m, 1455m, 1410m, 1385m, 
1240s, 1170m, 1050m, 700m. 1H-NMR (CDCl3): 7.49 (d, J = 8.1, NH); 7.45–7.05 (m, 15 
arom. H, NH); 6.92 (s, NH); 5.71 (t-like, NH); 5.16, 5.10 (AB, JAB = 12.2, PhCH2O); 4.8–4.7 
(m, CH(2)(Phe)); 4.41 (t, CH(2)(Pro));  3.9–3.7 (AB of ABX, CH2(Gly)); 3.61 (s, MeO); 3.4–
3.1, 3.1–2.95 (2m, 1:1, 2 PhCH2), CH2(5)(Pro)); 2.25–2.1, 1.85–1.65, 1.65–1.5 (3m, 1:2:1, 
CH2(3), CH2(4)(Pro)); 1.52, 1.50, 1.34 (3s, Me2C, Me(Phe(2Me))). 13C-NMR (CDCl3): 175.1, 
172.2, 171.6, 171.1, 169.0 (5s, 4 CO(amide), COOMe); 156.8 (s, CO(urethane)); 137.1, 
136.0, 134.5 (3s, 3 arom. C); 130.2, 129.2, 128.9, 128.6, 128.5, 128.2, 127.7, 126.5 (8d, 15 
arom. CH); 67.4 (t, PhCH2O); 63.6 (d, C(2)(Pro)); 60.1, 57.1 (2s, C(2)(Aib), 
C(2)(Phe(2Me))); 53.9 (d, CH(2)(Phe)); 52.0 (q, MeO); 48.6 (t, CH2(5)(Pro)); 44.8 (t, 
CH2(Gly)); 43.0, 37.9 (2t, 2 PhCH2); 28.3, 26.0 (2t, CH2(3), CH2(4)(Pro)); 26.7, 24.4, 24.0 
(3q, Me2C, Me(Phe(2Me))). ESI-MS: 736 (100, [M+Na]+).  
Z-Gly-(R)-Phe(2Me)-Pro-Aib-Phe-OMe ((R,S,S)-8g). Colorless solid. M.p. 165.5–
166.5°. [α]D = +68.9 (c = 1.04, EtOH). IR (KBr): 3400s, 3060m, 3030m, 2980m, 2940m, 
1750s, 1730s, 1655s, 1625s, 1545s, 1535s, 1500m, 1455m, 1445m, 1405m, 1385m, 1375m, 
1365m, 1305m, 1280m, 1240s, 1170m, 1160m, 1130w, 1100m, 1080m, 1045m, 1030m, 
1000m, 740m, 700m. 1H-NMR (CDCl3): 7.50 (d, J = 8.1, NH); 7.39 (s, NH); 7.4–7.0 (m, 15 
arom. H); 6.85 (s, NH); 5.70 (br. s, NH); 5.08 (s, PhCH2O); 4.75–4.65 (m, CH(2)(Phe)); 4.37 
(t-like, CH(2)(Pro)); 4.0–3.8 (AB of ABX, CH2(Gly)); 3.75–3.65, 3.35–3.2 (2m, CH2(5)(Pro)); 
3.61 (s, MeO); 3.42, 3.17 (AB, JAB = 13.8, PhCH2); 3.25–3.1, 3.1–2.95 (2m, PhCH2); 2.2–
2.05, 1.95–1.8, 1.8–1.6 (3m, 1:1:2, CH2(3), CH2(4)(Pro)); 1.46, 1.39, 1.26 (3s, Me2C, 
32 
 
Me(Phe(2Me))). 13C-NMR (CDCl3): 175.3, 172.5, 172.4, 171.2, 169.3 (5s, 4 CO(amide), 
COOMe); 156.8 (s, CO(urethane)); 136.8, 136.6, 136.1 (3s, 3 arom. C); 131.1, 129.1, 128.6, 
128.3, 128.22, 128.17, 128.1, 126.8, 126.6 (9d, 15 arom. CH); 67.2 (t, PhCH2O); 63.7 (d, 
CH(2)(Pro)); 59.1, 57.1 (2s, C(2)(Aib), C(2)(Phe(2Me))); 53.6 (d, CH(2)(Phe)); 52.0 (q, 
MeO); 48.7 (t, CH2(5)(Pro)); 44.4 (t, CH2(Gly)); 40.9, 37.8 (2t, 2 PhCH2); 28.5, 26.0 (2t, 
CH2(3), CH2(4)(Pro)); 27.0, 24.1, 21.1 (3q, Me2C, Me(Phe(2Me))). ESI-MS: 736 (100, 
[M+Na]+), 714 (10, [M+1]+), 535 (6, [M-PheOMe]+).  
Suitable crystals for the X-ray crystal-structure determination were grown from 
AcOEt/MeOH by slow evaporation of the solvent. 
3.9. Z-Gly-(R,S)-Phe(2Me)-Pro-Aib-Aib-N(Me)Ph (8h). According to GP 5, a mixture 
of 11 (1.25 g, 3.36 mmol) and H-Pro-Aib-Aib-N(Me)Ph [25b] (1.40 g, 3.73 mmol) in CH2Cl2 
(30 ml) was treated with TBTU (1.20 g, 3.74 mmol), HOBt (910 mg, 6.73 mmol), and DIEA 
(916 mg, 7.09 mmol) for 18 h. CC (CH2Cl2/MeOH 15:1) gave 1.76 g (72%) 8h. Separation of 
815.5 mg of the mixture of the diastereoisomers by PLC (AcOEt/MeOH 20:1, 5× developed) 
led to 224.6 mg of (S,S)-8h and 470.6 mg of (R,R)-8h. 
Z-Gly-(S)-Phe(2Me)-Pro-Aib-Aib-N(Me)Ph ((S,S)-8h). Colorless solid. M.p. 92.4–
93.9°. [α]D = +14.0 (c = 0.57, EtOH). IR (KBr): 3310s, 2980m, 2930m, 1730s, 1680s, 1660s, 
1630s, 1595m, 1545s, 1540s, 1530s, 1495s, 1465m, 1455m, 1405m, 1390s, 1360m, 1280m, 
1240s, 1200m, 1160m, 1090m, 1050m, 740m, 700s. 1H-NMR (CDCl3): 7.52 (s, NH); 7.35–
7.05 (m, 15 arom. H, 2 NH); 6.29 (br. s, NH); 5.12, 5.08 (AB, JAB = 12.3, PhCH2O); 4.22 (t, J 
= 8.3, CH(2)(Pro));  3.8–3.55 (AB of ABX, JAB = 17.2, CH2(Gly)); 3.38 (s, MeN); 3.2–3.0 (m, 
CH2(5)(Pro)); 2.91 (s, PhCH2); 2.3–2.15, 1.85–1.7, 1.7–1.4 (3m, 1:1:2, CH2(3), CH2(4)(Pro)); 
1.60, 1.57, 1.47, 1.45, 1.40 (5s, 2 Me2C, Me(Phe(2Me))). 13C-NMR (CDCl3): 174.7, 174.1, 
171.8, 171.6, 169.8 (5s, 5 CO(amide)); 157. (s, CO(urethane)); 146.1, 136.4, 134.6 (3s, 3 
arom. C); 130.1, 129.0, 128.8, 128.6, 128.3, 128.1, 127.6, 127.2, 126.6 (9d, 15 arom. CH); 
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67.0 (t, PhCH2O); 64.4 (d, C(2)(Pro)); 60.3, 57.2, 57.0 (3s, 2 C(2)(Aib), C(2)(Phe(2Me))); 
48.6, 44.6, 43.6 (3t, CH2(Gly), CH2(5)(Pro), PhCH2); 40.1 (q, MeN); 28.6, 26.2 (2t, CH2(3), 
CH2(4)(Pro)); 27.8, 26.4, 25.4, 24.3, 23.7 (5q, 2 Me2C, Me(Phe(2Me))). ESI-MS: 749 (100, 
[M+Na]+).  Anal. calc. for C40H50N6O7.0.5H2O (735.88): C 65.29, H 6.99, N 11.42; found: C 
65.28, H 7.17, N 11.15. 
Z-Gly-(R)-Phe(2Me)-Pro-Aib-Aib-N(Me)Ph ((R,S)-8h). Colorless solid. M.p. 168.7–
170.2°. [α]D = +114 (c = 0.51, EtOH). IR (KBr): 3300s, 3060w, 3030w, 2980w, 2940w, 
1725s, 1660s, 1625s, 1595m, 1540s, 1495m, 1465m, 1455m, 1410m, 1395m, 1375m, 1360m, 
1280m, 1240m, 1160m, 1135m, 1090m, 1050m, 705s. 1H-NMR (CDCl3): 7.44 (s, NH); 7.35–
7.05 (m, 15 arom. H, 2 NH); 5.95 (br. s, NH); 5.09 (s, PhCH2O); 4.23 (t, J = 8.3, CH(2)(Pro)); 
3.9–3.6 (AB of ABX, JAB = 17, CH2(Gly)); 3.7–3.6, 3.3–3.1 (2m, CH2(5)(Pro)); 3.37, 3.08 
(AB, JAB = 13.7, PhCH2); 3.29 (s, MeN); 2.3–2.15, 1.95–1.85, 1.85–1.6 (3m, 1:1:2, CH2(3), 
CH2(4)(Pro)); 1.54, 1.45, 1.39, 1.17 (4s, 1:1:2:1, 2 Me2C, Me(Phe(2Me))). 13C-NMR 
(CDCl3): 174.8, 173.9, 173.1, 171.3, 169.6 (5s, 5 CO(amide)); 156.8 (s, CO(urethane)); 145.9, 
136.5, 136.2 (3s, 3 arom. C); 131.2, 128.9, 128.6, 128.3, 128.2, 127.2, 126.8, 126.6 (8d, 15 
arom. CH); 67.1 (t, PhCH2O); 64.4 (d, CH(2)(Pro)); 58.9, 57.1 (2s, 2 C(2)(Aib), 
C(2)(Phe(2Me))); 48.8 (t, CH2(5)(Pro)); 44.2 (t, CH2(Gly)); 40.7 (t, PhCH2); 40.1 (q, MeN); 
28.7, 26.2 (2t, CH2(3), CH2(4)(Pro)); 27.7, 26.3, 25.6, 23.7, 20.9 (5q, 2 Me2C, 
Me(Phe(2Me))). ESI-MS: 749 (100, [M+Na]+), 620 (7, [M-N(Me)Ph]+).   
Suitable crystals for the X-ray crystal-structure determination were grown from 
AcOEt/MeOH/hexane by slow evaporation of the solvent. 
4. X-Ray Crystal-Structure Determination of 6a, 8a, (S,S)-8e, 8f, (R,S,S)-8g, (R,S)-8h, 
and 10 (see Table 4 and Figs. 1 – 7)9). The measurements were made using graphite-
9)  CCDC-989272–989278 contain the supplementary crystallographic data for this paper. 
These data can be obtained free of charge from The Cambridge Crystallographic Data 
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monochromated MoKα radiation (λ  0.7107 Å) on a Rigaku AFC5R diffractometer fitted to a 
12-kW rotating-anode generator.  The intensities were corrected for Lorentz and polarization 
effects. Empirical absorption corrections based on azimuthal scans of several reflections [45] 
were applied in the cases of 8f and (R,S,S)-8g. Equivalent reflections, other than Friedel pairs 
for structures in non-centrosymmetric space groups, were merged.  The data collection and 
refinement parameters are given in Table 4, and views of the molecules are shown in Figs. 1 – 
7.  Each structure was solved by direct methods using SHELXS86 [46] for 6a, 8a, (S,S)-8e, 
8f, (R,S,S)-8g, and 10, which revealed the positions of all non-H-atoms, and SnB [47]10) for 
(R,S)-8h, which revealed the positions of most of the non-H-atoms. In the latter case, the 
remaining non-H atoms were located in a subsequent difference electron density map. For all 
structures, the non-H-atoms were refined anisotropically. Unless indicated otherwise fro 
individual structures below, H-atoms on heteroatoms were generally placed in the positions 
indicated by difference electron density maps and their positions were allowed to refine 
together with individual isotropic displacement parameters. All other H-atoms were placed in 
geometrically calculated positions and refined by using a riding model, with Uiso(H) =  
1.2Ueq(parent atom) (1.5Ueq for Me groups). 
In the case of 6a, the Ph ring of the middle benzyl group of the molecule is disordered 
over two orientations. The site occupation factor for the major conformation refined to 
0.645(19). Similarity restraints were applied to the chemically equivalent bond lengths and 
angles involving all disordered C-atoms, while neighbouring atoms within and between each 
Centre via www.ccdc.cam.ac.uk/data_request/cif. 
10)  We are grateful to R. Miller and C. Weeks of The Hauptman-Woodward Medical 
Research Institute, Buffalo, who carried out the solution of the structure using what 
was, at the time in 1996, a new, unreleased version of their program, SnB. Without their 
assistance, this structure determination would not nave been successful. 
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conformation of the disordered ring were restrained to have similar atomic displacement 
parameters. There are disordered solvent molecules present in the crystal lattice, and these lie 
across centres of inversion, so that the ratio of peptide to solvent molecules is 2:1. The solvent 
appears to be a hexane molecule which has two orientations, although the end atoms in one 
orientation may be further disordered. As the disorder could not be modelled adequately, the 
contribution of the solvent molecules to the intensity data was removed by using the 
SQUEEZE routine [48] of the PLATON program [49]. Omission of the solvent molecules 
leaves two cavities of 217 Å3 per unit cell. The number of electrons contributing to each void 
in the structure was calculated by the SQUEEZE routine to be approximately 41 e, although 
this may be an underbound. Allowing for one hexane molecule per cavity yields 50 e and this 
assumption was used in the subsequent calculation of the empirical formula, formula weight, 
density, linear absorption coefficient and F(000). 
In the case of (S,S)-8e, the terminal benzyl group is disordered over two orientations 
with a site occupation factor for the major conformation of 0.669(5). Similarity restraints 
were applied to the chemically equivalent bond lengths and angles involving all disordered C-
atoms, while neighbouring atoms within and between each conformation of the disordered 
group were restrained to have similar atomic displacement parameters. The terminal methyl 
ester group might also be slightly disordered, because the atomic displacement parameters of 
these atoms, particularly O(24), are large. However the disorder could not be resolved 
reasonably and average positions were used for the atoms of this region of the molecule. As a 
result the C(24)=O(24) bond appears to be somewhat shorter than it should be. The 
asymmetric unit also contains two sites which are partially occupied by water molecules. 
Initial refinement of the site occupation factors of these molecules gave values close to 0.5 
and in the final refinement the site occupation factors of the water molecules were set to 0.5. 
H-atoms were not included for the water molecules. 
36 
 
The crystals of 8f rapidly lost included solvent on standing in air. The asymmetric unit 
contains one peptide molecule plus approximately one third of a highly disordered hexane 
molecule which sits across a centre of inversion. As the disorder could not be modelled 
adequately, the contribution of the solvent molecules to the intensity data was removed by 
using the SQUEEZE routine of the PLATON program.  Omission of the solvent molecules 
leaves four cavities of 128 Å3 per unit cell.  The number of electrons contributing to each void 
in the structure was calculated by the SQUEEZE routine to be approximately 31 e.  Allowing 
for two thirds of a hexane molecule per cavity yields 30 e, which leads to a peptide:hexane 
ratio in the structure of 3:1 and this assumption was used in the subsequent calculations. The 
amide H-atoms were placed in geometrically calculated positions and refined as described 
above for riding H-atoms. 
In the case of (R,S,S)-8g, the asymmetric unit contains one peptide molecule, one 
AcOEt molecule, and one partially occupied site for a H2O molecule. The site occupation 
factor for the O-atom of H2O was initially refined and then fixed at 0.5. The H-atoms of the 
H2O molecule were included in the positions obtained from a difference electron density map 
and then constrained to ride on the parent O-atom with Uiso(H) = 1.5Ueq(O). 
The asymmetric unit of (R,S)-8h contains two peptide, one hexane, and one half of a 
H2O molecule, where the latter sits on a two-fold axis. One of the peptide molecules has a 
disordered Ph ring in the Z group. Two sets of positions were defined for the atoms of this Ph 
ring and the site occupation factor of the major conformation of the ring refined to 0.504(1).  
Similarity restraints were applied to the chemically equivalent bond lengths and angles 
involving all disordered C-atoms, the C–C bonds were restrained to 1.395(5) Å, the two 
conformations of the ring were restrained to be planar, and neighbouring atoms within and 
between each conformation of the disordered Ph ring were restrained to have similar atomic 
displacement parameters. The amide H-atoms were placed in geometrically calculated 
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positions and refined as described above for riding H-atoms. The position of the symmetry-
unique water H-atom was refined with Uiso(H) = 1.5Ueq(O). 
In the case of 10, the asymmetric unit contains one molecule of the peptide plus a 
disordered molecule of MeOH. The site occupation factor of the major orientation of the 
MeOH molecule refined to 0.659(14). Neighbouring atoms within and between each 
conformation of the disordered MeOH molecule were restrained to have similar atomic 
displacement parameters. The amide and peptide hydroxy H-atoms were placed in 
geometrically calculated positions and refined as described above for riding H-atoms; for the 
hydroxy H-atom Uiso(H) = 1.5Ueq(O). The hydroxy H-atoms of the MeOH molecules were not 
included in the model. 
The refinement of each structure was carried out on F2 by using full-matrix least-
squares procedures, which minimized the function Σw(Fo2 – Fc2)2. A correction for secondary 
extinction was applied in the case of 6a and (R,S)-8h. Neutral atom scattering factors for non-
H-atoms were taken from [50], and the scattering factors for H-atoms were taken from [51].  
Anomalous dispersion effects were included in Fc [52]; the values for ƒ’ and ƒ” were those of 
[53].  The values of the mass attenuation coefficients are those of [54].  All refinements were 
performed using SHELXL-2013 [55]. 
 
Table 4.  Crystallographic Data for Compounds 6a, 8a, (S,S)-8e, 8f, (R,S,S)-8g, (R,S)-
8h, and 10 
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Legends 
 
Fig. 1. ORTEP Plot [32] of the molecular structure of the tetrapeptide 6a (50% probability 
ellipsoids, arbitrary numbering of atoms, H-atoms bonded to C-atoms omitted for clarity and only 
the major conformation of the disordered central benzyl ring is shown, solvent molecule not 
included) 
 
Fig. 2. ORTEP Plot [32] of the molecular structure of the pentapeptide 8a (50% 
probability ellipsoids, arbitrary numbering of atoms, H-atoms bonded to C-atoms omitted for 
clarity) 
 
Fig. 3. ORTEP Plot [32] of the molecular structure of the pentapeptide 8f (50% probability 
ellipsoids, arbitrary numbering of atoms, H-atoms bonded to C-atoms omitted for clarity, solvent 
molecule not included) 
 
Fig. 4. ORTEP Plot [32] of the molecular structure of the pentapeptide (S,S)-8e (50% 
probability ellipsoids, arbitrary numbering of atoms, H-atoms bonded to C-atoms omitted for 
clarity and only the major conformation of the disordered terminal benzyl group is shown, water 
molecules not included) 
 
Fig. 5. ORTEP Plot [32] of the molecular structure of the pentapeptide (R,S,S)-8g (50% 
probability ellipsoids, arbitrary numbering of atoms, H-atoms bonded to C-atoms omitted for 
clarity, solvent molecules not included) 
 
Fig. 6. ORTEP Plot [32] of the molecular structure of one of the two symmetry-
independent molecules of the pentapeptide (R,S)-8h (50% probability ellipsoids, arbitrary 
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numbering of atoms, H-atoms bonded to C-atoms omitted for clarity, solvent molecules not 
included) 
 
Fig. 7. ORTEP Plot [32] of the molecular structure of the pentapeptide 10 (50% 
probability ellipsoids, arbitrary numbering of atoms, H-atoms bonded to C-atoms omitted for 
clarity, solvent molecule not included) 
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Table 1. 13C-NMR Chemical Shifts of C(β) and C(γ) of the Pro Residue in Pro-Containing 
Pentapeptides 
 
Peptide 
 
Solvent 
 
C(β) [ppm] 
 
C(γ) [ppm] 
 
Z-Gly-Aib-Pro-Aib-Aib-N(Me)Ph (8d) 
Z-Gly-(R)-Phe(2Me)-Pro-Aib-Phe-OMe ((R,S,S)-8g) 
Z-Gly-(S)-Phe(2Me)-Pro-Aib-Phe-OMe ((S,S,S)-8g) 
Z-Gly-(R)-Phe(2Me)-Pro-Aib-Aib-N(Me)Ph ((R,S)-8h) 
Z-Gly-(S)-Phe(2Me)-Pro-Aib-Aib-N(Me)Ph ((S,S)-8h) 
Z-Gly-Aib-Pro-Aib-Aib-OH (10) 
 
CDCl3 
CDCl3 
CDCl3 
CDCl3 
CDCl3 
(D6)DMSO 
 
28.8 
28.5 
28.3 
28.7 
28.6 
28.2 
 
26.2 
26.0 
26.0 
26.3 
26.2 
25.5 
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Table 2. Torsion Angles φ, ψ, and ω of the Backbone of Compounds 8a, (S,S)-8e, 8f, 
(R,S,S)-8g, (R,S)-8h, and 10  in the Crystal (Amino Acid (i) = Gly(1)) 
 
 
 
 
 
 8a (S,S)-8e 8f (R,S,S)-8g R,S)-8h 10 
φ(i) 
ψ(i) 
ω(i) 
53.7(2) 
32.4(2) 
–178.7(1) 
–96.3(3) 
–5.6(5) 
173.2(3) 
–88.7(5) 
–33.9(6) 
178.7(4) 
70.6(5) 
179.0(4) 
179.4(4) 
64(1); 62(1) 
–170.3(7); –172.3(7) 
175.1(7); 177.9(7) 
82.2(6) 
155.3(5) 
–169.2(4) 
φ(i+1) 
ψ(i+1) 
ω(i+1) 
55.8(2) 
21.8(2) 
–178.7(1) 
53.9(4) 
34.3(5) 
179.5(3) 
49.4(6) 
42.2(6) 
173.1(4) 
–49.6(5) 
–43.4(5) 
–173.7(4) 
–51.5(9); –51.0(9) 
–36(1); –40.5(9) 
–178.9(7); –177.8(6) 
–53.8(6) 
–37.8(6) 
–176.9(4) 
φ(i+2) 
ψ(i+2) 
ω(i+2) 
51.9(2) 
29.6(2) 
178.6(1) 
61.3(5) 
13.5(5) 
–170.8(3) 
61.3(6) 
29.4(6) 
–177.5(4) 
–66.2(5) 
–13.6(6) 
171.5(4) 
–55 (1); –57(1) 
–30(1); –30 (1) 
–179.0(7); –178.1(7) 
–61.2(6) 
–31.7(6) 
178.7(4) 
φ(i+3) 
ψ(i+3) 
ω(i+3) 
57.0(2) 
30.4(2) 
166.3(1) 
55.8(4) 
30.6(5) 
163.6(4) 
59.4(6) 
32.4(6) 
–170.7(4) 
–55.6(5) 
–32.0(5) 
–172.5(4) 
–64.8(9); –58.4(9) 
–30(1); –32.6(9) 
–162.1(8); –154.6(7) 
–54.1(7) 
–39.5(5) 
175.4(4) 
φ(i+4) 
ψ(i+4) 
–83.0(2) 
162.8(1) 
–81.0(5) 
–179.1(4) 
–47.4(7) 
–57.4(7) 
–111.0(5) 
179.4(4) 
–57(1); –52(1) 
–50(1); –54(1) 
49.4(6) 
45.2(6) 
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Table 3.  Intramolecular H-Bonds of Compounds 8a, (S,S)-8e, 8f, (R,S,S)-8g, (R,S)-8h, and 
10 (atom numbering refers to Figs. 1 – 7) 
 
Compound N(1)–H….O(8) 
N….O (Å)    N–H….O (°) 
N(4)–H….O(11) 
N….O (Å)    N–H….O (Å) 
N(7)–H….O(14) 
N….O (Å)    N–H….O (Å) 
8a  2.928(2)      163(2)    3.052(2)      171(2) 3.013(2)       166(1) 
(S,S)-8e 3.007(4)      165(4) 2.872(4)      166(4) - 
8f 2.976(5)      130 2.977(5)      141 - 
(R,S,S)-8g 2.960(5)      162(4) 3.001(5)      161(4) - 
(R,S)-8h 2.974(8)      163; 
3.055(7)      168 
3.036(8)      149; 
3.067(8)      147 
- 
10 3.034(5)      126 3.000(5)      140 - 
                         
 
 
 
 
48 
 
Table 4.  Crystallographic Data for Compounds 6a, 8a, (S,S)-8e, 8f, (R,S,S)-8g, (R,S)-8h, and 10 
______________________________________________________________________________________________ 
 
 6a 8a (S,S)-8e 
______________________________________________________________________________________________ 
Crystallized from CH2Cl2/Et2O/hexane CH2Cl2/hexane AcOEt/hexane 
Empirical formula C35H43N5O6.0.5C6H14 C31H41N5O8 C36H43N5O8.H2O 
Formula weight 672.84 611.69 691.78 
Crystal color, habit colorless, prism colorless, prism colorless, irregular prism 
Crystal dimensions [mm] 0.23 × 0.25 × 0.45 0.33 × 0.41 × 0.43 0.25 × 0.27 × 0.50 
Temperature [K] 173(1) 173(1) 173(1) 
Crystal system monoclinic monoclinic orthorhombic 
Space group P21/n P21/n P212121 
Z 4 4 4 
Reflections for cell determination 22 25  25 
2θ range for cell determination [°] 32–39 38–40 23–33 
Unit cell parameters a [Å] 11.642(3) 13.698(3) 15.347(4) 
 b [Å] 15.135(3) 13.979(4) 24.232(4) 
 c [Å] 21.307(2) 17.409(3) 10.028(4) 
 α [°] 90 90 90 
 β [°] 97.294(12) 109.133(14) 90 
 γ [°] 90 90 90 
 V [Å3] 3724(1) 3150(1) 3729(2) 
Dx [g cm-3] 1.200 1.290 1.232 
µ(MoKα) [mm-1] 0.817  0.0940 0.0892 
Scan type ω/2θ ω/2θ ω 
2θ(max) [°] 55 60 55 
Transmission factors (min; max) - - - 
Total reflections measured 9296 9898 5535 
Symmetry independent reflections 8539 9182 5389 
Reflections used [I > 2σ(I)]  4362  6222 3892 
Parameters refined; restraints 484; 164 423; 0 548; 202 
Final R(F)  [I > 2σ (I) reflections] 0.0577  0.0454 0.0549 
 wR(F2) (all data) 0.1671  0.1262 0.1682 
Weighting parameter (a; b)a) 0.0830; 0 0.0525; 0.4262 0.0886; 0.8267 
Secondary extinction coefficient 0.0022(6) - - 
Goodness of fit 0.927 1.034 1.058 
Final ∆max/σ 0.000 0.000 0.000 
∆ρ (max; min) [e Å–3] 0.29; –0.24 0.37; –0.18 0.79; –0.26 
______________________________________________________________________________________________ 
a) w–1 = σ2 (Fo2) + (aP)2 + bP, where P = (Fo2 + 2Fc2)/3 
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Table 4.  Crystallographic Data for Compounds 6a, 8a, (S,S)-8e, 8f, (R,S,S)-8g, (R,S)-8h, and 10 (continued) 
________________________________________________________________________________________________ 
 
 8f (R,S,S)-8g (R,S)-8h 
________________________________________________________________________________________________ 
Crystallized from AcOEt/hexane MeOH/AcOEt AcOEt/MeOH/hexane 
Empirical formula C37H46N6O7.0.33C6H14 C39H47N5O8.C4H8O2.0.5H2O C40H50N6O7.0.5C6H14. 0.25H2O 
Formula weight 715.33 810.94 774.46 
Crystal color, habit colorless, plate colorless, plate colorless, hexagonal prism 
Crystal dimensions [mm] 0.10 × 0.38 × 0.42 0.20 × 0.45 × 0.50 0.36 × 0.36 × 0.38 
Temperature [K] 173(1) 173(1) 173(1) 
Crystal system orthorhombic orthorhombic trigonal 
Space group Pbca P212121 P3121 
Z 8 4 12 
Reflections for cell determination 25 25  25 
2θ range for cell determination [°] 21–25 24–35 20–27 
Unit cell parameters a [Å] 25.465(4) 16.601(5) 15.706(6) 
 b [Å] 20.729(6) 26.785(8) 15.706(6) 
 c [Å] 14.536(5) 9.720(6) 60.971(6) 
 α [°] 90 90 90 
 β [°] 90 90 90 
 γ [°] 90 90 120 
 V [Å3] 7673(4) 4322(3) 13026(11) 
Dx [g cm-3] 1.239 1.246 1.185 
µ(MoKα) [mm-1] 0.0860  0.0895 0.0813 
Scan type ω ω ω 
2θ(max) [°] 50 50 50 
Transmission factors (min; max) 0.806; 1.000 0.903; 1.000 - 
Total reflections measured 8431 5016 29374 
Symmetry independent reflections 6768 4874 15416 
Reflections used [I > 2σ(I)]  2204  3299 8853 
Parameters refined; restraints 457; 0 554; 0 1087; 187 
Final R(F)  [I > 2σ (I) reflections] 0.0701  0.0446 0.0787 
 wR(F2) (all data) 0.1842  0.1104 0.2097 
Weighting parameter (a; b)a) 0.0781; 0 0.0392; 0.9522 0.0641; 16.507 
Secondary extinction coefficient - - 0.0014(2) 
Goodness of fit 0.790 1.013 1.057 
Final ∆max/σ 0.000 0.000 0.002 
∆ρ (max; min) [e Å–3] 0.32; –0.25 0.19; –0.21 0.42; –0.38 
______________________________________________________________________________________________ 
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Table 4.  Crystallographic Data for Compounds 6a, 8a, (S,S)-8e, 8f, (R,S,S)-8g, (R,S)-8h, and 10 (continued) 
_______________________________________________________________________________________ 
 
 10  
_______________________________________________________________________________________ 
Crystallized from MeOH  
Empirical formula C27H39N5O8.CH4O  
Formula weight 593.67  
Crystal color, habit colorless, prism  
Crystal dimensions [mm] 0.18 × 0.33 × 0.50  
Temperature [K] 173(1)  
Crystal system orthorhombic  
Space group P212121  
Z 4  
Reflections for cell determination 17  
2θ range for cell determination [°] 20–26  
Unit cell parameters a [Å] 12.983(9)  
 b [Å] 10.249(5)  
 c [Å] 23.918(7)  
 α [°] 90  
 β [°] 90  
 γ [°] 90  
 V [Å3] 3183(3)  
Dx [g cm-3] 1.239  
µ(MoKα) [mm-1] 0.0928   
Scan type ω/2θ  
2θ(max) [°] 55  
Transmission factors (min; max) -  
Total reflections measured 4118  
Symmetry independent reflections 4090  
Reflections used [I > 2σ(I)]  2798   
Parameters refined; restraints 407; 36  
Final R(F)  [I > 2σ (I) reflections] 0.0611   
 wR(F2) (all data) 0.1975   
Weighting parameter (a; b)a) 0.0808; 2.3471  
Secondary extinction coefficient - 
Goodness of fit 1.085  
Final ∆max/σ 0.000  
∆ρ (max; min) [e Å–3] 0.33; –0.36  
_____________________________________________________________________________________ 
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